



**Vaccines and Global Health: The Week in Review**  
**23 October 2021 :: Issue 629**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

A. Milestones :: Perspectives :: Featured Journal Content

B. Emergencies

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

## ***Milestones :: Perspectives :: Research***

.....  
.....

### **House-to-house polio vaccination set to recommence across Afghanistan in November**

KABUL / AMMAN / KATHMANDU, 18 October 2021 – WHO and UNICEF welcome the decision by the Taliban leadership supporting the resumption of house-to-house polio vaccination across Afghanistan.

The vaccination campaign, which begins on November 8, will **be the first in over three years to reach all children in Afghanistan, including more than 3.3 million children in some parts of the country who have previously remained inaccessible to vaccination campaigns. A second nationwide polio vaccination campaign has also been agreed and will be synchronised with Pakistan's own polio campaign planned in December.**

"This is an extremely important step in the right direction," said Dapeng Luo, WHO Representative in Afghanistan. "We know that multiple doses of oral polio vaccine offer the best protection, so we are pleased to see that there is another campaign planned before the end of this year. Sustained access to all children is essential to end polio for good. This must remain a top priority," he said.

With only one case of wild poliovirus reported so far in 2021, Afghanistan has an extraordinary opportunity to eradicate polio. Restarting polio vaccination now is crucial for preventing any significant resurgence of polio within the country and mitigating the risk of cross-border and international transmission...

The safety and security of health workers remain a prime concern for the polio programme. **The Taliban leadership has expressed their commitment for the inclusion of female frontline workers and for providing security and assuring the safety of all health workers across the country,** which is an essential prerequisite for the implementation of polio vaccination campaigns.

WHO and UNICEF call on authorities and community leaders at all levels to respect and uphold the neutrality of health interventions and ensure unhindered access to children now and for future campaigns.

.....  
.....

### **Over 80 million reached as Africa trailblazes novel polio vaccine**

22 October 2021

Brazzaville – More than 80 million children have been vaccinated with the novel oral polio vaccine type 2 (nOPV2) in six countries in Africa, the world's first region to rollout of the vaccine just months after the World Health Organization (WHO) gave it Emergency Use Listing status in November 2020.

**Nigeria became the first country in the world to use nOPV2 to tackle an outbreak in March 2021, vaccinating 7 million children in six states. By September, Benin, Congo, Liberia, Niger and Sierra Leone had also rolled out the vaccine.** Africa was certified free of wild polio in August 2020, but outbreaks of circulating vaccine-derived polio type 2 are still being reported...

The nOPV2 is a modified form of the monovalent oral polio vaccine designed to be more genetically stable and less likely to, in under-immunized populations, revert to a form that can cause permanent paralysis in children from vaccine-derived poliovirus. Given the urgent public health need to address vaccine-derived polio globally, nOPV2 became the first vaccine to receive authorization for use under Emergency Use Listing (EUL). WHO has urged countries to rapidly implement the process for national approval for importation and deployment of the vaccine once it was approved for use.

"Africa's trailblazing rollout of the novel polio vaccine shows a true determination to ending polio for good. **The progress made by the six countries and the upcoming rollout in five additional countries targeting 30 million children by the end of 2021 promise effective and lasting protection from the threat of lifelong paralysis,**" said Dr Pascal Mkanda, Polio Eradication Programme Coordinator at WHO Regional Office for Africa...

.....  
.....

## WHO-SAGE - October 2021 Meeting

### *Editor's Note:*

In last week's edition, we presented the full text of [SAGE October 2021 meeting highlights](#). WHO has added the [link to the slide presentations](#) supporting 30+ sessions in the [meeting agenda](#). We include two sample slides from the [presentation on IA2030](#) as examples of the content available.

Session2.1\_Lindstrand\_Mast

## SAGE and IA2030: new approaches build on GVAP learning

### *Learnings from GVAP key challenges*

- **No clear ownership or governance structure** in place for immunization
- **Monitoring was not linked** strongly enough to corrective action
- Issues with ownership and monitoring/action led to **limited accountability**
- Need for greater country and/or regional differentiation, **promoting national ownership**
- Need for better information-sharing and visibility for contributions across **all partners/sectors**
- Limited alignment across organizations (and to global strategies SDGs, UHC)
- **Advocacy efforts** and high visibility not maintained throughout the decade

SAGE meeting October 2021

### *New ownership & accountability approaches in IA2030*

- A new leadership body formed (**IA2030 Partnership Council**, with senior political leaders and partner representatives)
- **IAPC to report biannually to WHA**, incorporating the key recommendations from SAGE independent review of results (no more separate reporting from SAGE)
- More **flexible approach to M&E** to facilitate realistic regional and national target setting and promote country ownership
- **Regional models of monitoring** linked to action to promote continuous quality improvement cycles at the country level
- **IA2030 Working Groups** formed to identify, discuss and align on the most significant challenges and innovative new practices and act as strategic priority "champions", providing an annual commentary on data relating to their areas of interest and making recommendations to countries, partners and stakeholders
- Long-term strategic approach to **communications and advocacy**

27

## Session 2-1: Understanding the Partnership Council membership: 2021-2023



Partner	Name & Title
1. UNICEF	Dr Omar Abdi, Deputy Executive Director, Programmes
2. WHO	Dr Zsuzsanna Jakab, Deputy Director General
3. Gavi Secretariat	Dr Anuradha Gupta, Deputy CEO
4. Bill & Melinda Gates Foundation	Dr Orin Levine, Director, Global Delivery Programs
5. The World Bank	Dr Juan Pablo Uribe, Global Director, Health, Nutrition and Population
6. US Centers for Disease Control and Prevention	Dr Kevin Cain, Principal Deputy, Center for Global Health
7. US National Institutes of Health/NIAID	Dr B. Fenton Hall, Chief, Parasitology & International Programs Branch Division of Microbiology & Infectious Diseases
8. International Federation of the Red Cross	Mr Xavier Castellanos, Under Secretary General, National Society Development and Operations Coordination
9. Gavi CSO Constituency	Sheetal Sharma (interim representative)
10. Regional Directors from WHO (2) and from UNICEF (1)	a) Ms Marie-Pierre Poirier, UNICEF Director for West and Central Africa b) Dr Poonam Khetrpal Singh, Regional Director SEARO, WHO c) Dr Ahmed Al Mandhari, Regional Director EMRO, WHO
11. Representatives of the African Union (AU) and the European Union (EU)	a) Ms Isabel de la Mata, Principal Advisor for Health and Crisis Mgmt, European Commission, DG Health and Food Safety b) To be determined

37

.....  
.....

### As COVID-19 vaccine output estimated to reach over 12 billion by year end and 24

19 October 2021 IFPMA Press Release

- This month, COVID-19 vaccine manufacturing output will pass the 9.3 billion dose mark. The biopharmaceutical industry renews its May commitment to the G20 to collaborate with governments to support effective solutions to urgently address vaccine equity.
- At current production rates, swiftly rolling out vaccines to those who still need them looks achievable, if the political will, planning and collective action efforts are redoubled. **The G20 can play a critical role in focusing political attention on ramping up dose sharing, addressing bottlenecks in the supply chain and supporting country preparedness.**
- With COVID-19 vaccine supplies on track to outstrip global demand and voluntary collaborations with innovative vaccine manufacturers set to change Africa's vaccine manufacturing landscape in years to come, initiatives such as the proposed Intellectual Property TRIPS waiver are a distraction. All efforts should be directed towards advancing vaccinations.

19 October 2021, Geneva – **As G20 heads of state and government prepare to meet in Rome on 30-31 October, COVID-19 vaccine production will reach the 9,3 billion doses mark.** Of the world's 5.8 billion adult population, 3.3 billion people have been vaccinated<sup>[1]</sup>. Urgent steps need to be taken to advance vaccinations programmes that reach the remaining 2.5 billion adults. The biopharmaceutical industry renews the commitment it made to the G20 in May 2021 to work with governments to support these efforts. **The vaccine production effort is estimated to reach 12.5 billion doses by the end of 2021 and double again to 24 billion doses by June 2022, at which time vaccine supplies will most likely outstrip global demand.** These numbers show

that the premise for the Intellectual Property TRIPS waiver proposed a year ago, to help address an assumed shortage of vaccines as the solution to vaccine equity, has been overtaken by the facts. The solution to vaccine equity today resides in dose sharing, continuing to optimize output through manufacturing scaling up and voluntary licensing; as well as working together to enable countries to efficiently and effectively vaccinate their people...

...COVID-19 vaccine manufacturing output, driven principally by USA, EU, China, and India, is now amounting to over 1 billion vaccines each month. The 9.3 billion COVID-19 vaccine dose output by the end of October, and the estimated production of 12.5 billion by the end of the year, demonstrates the industry's success in trebling global vaccine capacity in less than a year. In addition, major strides have been made over the past year to support production capacity with vaccine manufacturers setting up over 300 voluntary collaborations. In particular in Africa, a number of important agreements and commitments have been made to share know-how of mRNA and adenoviral vector vaccine platforms via voluntary collaborations. Building on this, efforts must continue towards working together to vaccinate people in those parts of the world where vaccination rates are too low, including working to ensure countries are prepared to roll out vaccinations.

Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) proposes: "As an industry, we have put our energies into developing and producing treatments and vaccines against SARS-CoV-2. The numbers show that the scale up of vaccines is on track to ensure that everybody who needs to be vaccinated can be. We see a turning of the tide. The supplies are available; now all efforts should be focused on distributing and sharing doses. It would be our hope that the energy focused on undermining intellectual property could be channelled into collectively addressing vaccine equity, supporting the growing political will of G20 countries to ensure the necessary, collective action to get jabs into arms; we all agree this is the right thing to do."

.....  
.....

### **Health and Care Worker Deaths during COVID-19 - WHO**

20 October 2021

Health and care workers are the foundation of health systems and the driving force to achieving universal health coverage and global health security. Their commitment and professionalism throughout the pandemic are evident to all: extraordinary people, performing extraordinary work.

However, too many of them have become infected, ill or died as a result of COVID-19.

**WHO estimates that between 80 000 and 180 000 health and care workers could have died from COVID-19 in the period between January 2020 to May 2021, converging to a medium scenario of 115 500 deaths<sup>1</sup>.**

These deaths are a tragic loss. They are also an irreplaceable gap in the world's pandemic response. Encouragingly, the reported rate of infections and deaths among health and care workers has reduced over time: but the world cannot be complacent. More work is needed to minimize the risk of infection in the workplace.

**As of September 2021, available data from 119 countries suggest that two in five health and care workers were fully vaccinated on average, with considerable difference across regions and economic groupings. Fewer than 1 in 10 have been fully vaccinated in the African and Western Pacific regions, while 22 mostly high income countries reported that above 80% of their personnel are fully vaccinated.**

The Steering Committee of the International Year of Health and Care Workers, in coordination with a press conference with WHO Director General Dr Tedros Adhanom Ghebreyesus, issued a joint statement underscoring their deep concern about the probable number of deaths, the overall low rate of vaccinations and the vaccines inequities among health and care workers in low- and middle-income countries.

**The Joint Statement calls for immediate and concrete action to protect health and care workers:**

- 1. Strengthen data collection and reporting on infections, ill-health and deaths among health and care workers due to COVID-19;**
- 2. Protect health and care workers during and beyond the current global COVID-19 pandemic; and**
- 3. Accelerate the vaccination of all health and care workers in all countries.**

Failure to take action undermines the physical, mental, and social well-being of those individuals we depend upon to manage the pandemic. Recognition and commemoration are not enough. It is our moral obligation to protect and invest in health and care workers. And we must move forward together.

.....  
.....

## **COVID Vaccines – OCHA:: HDX**

### **[COVID-19 Data Explorer: Global Humanitarian Operations](#)**

#### ***COVID-19 Vaccine Roll-out***

**23 Oct 2021** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 239M total confirmed cases; 4.9M total confirmed deaths**

**Global vaccines administered: 6.64B**

Number of Countries: 29 [29 week ago]

COVAX Allocations Round 4-6 (Number of Doses): 120M [120M week ago]

COVAX Delivered (Number of Doses): 120M [110M week ago]

Other Delivered (Number of Doses): 200M [190M week ago]

Total Delivered (Number of Doses): 320M [300M week ago]



Total Administered (Number of Doses): 2560M [240M week ago]

.....  
.....

## **Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]**

A joint initiative from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-

income countries. Website accessed **23 Oct 2021**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





## Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### Weekly Epidemiological and Operational updates

Last update: 23 Oct 2021

**Confirmed cases ::** 242 348 657 [239 437 517 week ago]

**Confirmed deaths ::** 4 927 723 [4 879 235 week ago]

**Vaccine doses administered:** 6 655 399 359 [6 495 672 0 32 week ago]

### Weekly epidemiological update on COVID-19 - 19 October 2021


#### Overview

Globally, the numbers of weekly COVID-19 cases and deaths has stabilized this week, with over 2.7 million cases and over 46 000 new deaths, a 4% and 2% decrease respectively, representing similar numbers as those reported last week's. With the exception of the European region, which for the third consecutive week reported an increase in new COVID-19 cases (7% increase as compared with the previous week), all the other regions reported a decline. The largest decrease in new weekly cases was reported from the African Region (18%), followed by the Western Pacific Region (17%). The cumulative number of confirmed cases reported globally is now over 240 million and the cumulative number of deaths is over 4.8 million.

The number of new weekly deaths reported globally also showed a stabilization (2% decrease as compared with the previous week), with similar numbers as those reported last week's in the European region (4% increase), Western Pacific region (1% increase) and the American region (1% decrease). The largest decline in new weekly deaths was reported from the African region showing a 24% decrease as compared to the previous week.


In this edition, we provide updates on the evolution and geographic distribution of SARS-CoV-2 Variants of Concern (VOCs), and summarise phenotypic characteristics (transmissibility, disease severity, risk of reinfection, and impacts on diagnostics and vaccine performance) of VOCs based on published studies.

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 17 October 2021\*\***



\*\*See Annex 3: Data, table and figure notes





.....  
.....

## Director General Speeches

22 October 2021

Speech

### [WHO Director-General's opening remarks at the 9th meeting of the IHR Emergency Committee on COVID-19 – 22 October 2021](#)

...Inequitable access to vaccines and other life-saving tools means that a large proportion of the world's population remains susceptible to infection and at increased risk of severe disease and death.

**As you know, we have set a target to vaccinate 40% of the population of every country by the end of this year. 82 countries are at risk of missing that target.** For most of those countries, it's simply a problem of insufficient and unpredictable supply. A small group of countries have some limitations in their ability to absorb vaccines, and we are working to address those problems.

Recent months have also shown the importance of monitoring vaccine protection.

Data show that vaccines slow but don't fully stop transmission; however, they are very effective at protecting against symptomatic and severe disease as well as hospitalization and death caused by the Delta variant.

However, given the still-unknown benefits of revaccinating the general population, WHO has decided that additional doses should be targeted to at-risk population groups, such as those who are immunocompromised and older people...

21 October 2021

Speech

[WHO Director-General's opening remarks at the media briefing on COVID-19 - 21 October 2021](#)

21 October 2021

Speech

[Director-General's opening remarks at Member States Information Session on COVID-19 - 21 October 2021](#)

19 October 2021

Keynote

[Director-General's speech on building health systems resilience during COVID-19 and beyond](#)

■■■■■

■■■■■

[Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 29 September 2021](#)





For 23 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date












*[Full scale view available at title link above]*

Vaccines

Guidance Document  
20 October 2021

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Mibe (Dermapharm) Germany (DP) – Delpharm, Saint-Remy FRANCE (DP) – Shelf life extension: 09 months at -70 to -90°C – Sanofi-Aventis Deutschland GmbH Germany Diluent suppliers: – Pfizer Perth, Australia Fresenius Kabi, USA	31/12/2020  30/06/2021 08/07/2021 16/07/2021 17/09/2021 20/09/2021 06/10/2021
			USFDA				✓	Finalized: – Pharmacia & Upjohn, Kalamazoo (DPIPGS) McPherson (DP) – Exelead, Inc. Indianapolis USA	18/06/2021  16/07/2021 16/07/2021 30/09/2021
2.	 AstraZeneca, AB	AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
3.		AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional sites: – SK-Catalent – Wuxi (DS) – Chemo Spain – Amylin Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021
4.		AZD1222 Vaxzevria	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	09 July 2021
5.		AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	09 July 2021
6.								Additional site: Siam Bioscience Co., Ltd Thailand	11 October 2021
7.									
7.	 Serum Institute of India Pvt. Ltd	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
8.	 Janssen-Cilag International NV	Ad26.COV2.S	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites)	12 March 2021
							Additional sites: – Merck, Durham, UK (DS) – Merck, West Point/PA (DP)	Finalized: – Aspen RSA (DP) – Catalent Agnani Italy (DP) – Future submission – Ongoing	-25 June 2021 - 02 July 2021 - As submitted - TBC

Vaccines							Guidance Document 20 October 2021		
	Manufacturer /	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
9.		mRNA-1273	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)		✓	✓	Finalized	30 April 2021
				mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized ModernaTx. Norwood (DS) - Catalent Indiana, LLC (DP) - Lonza Biologics, Inc. Portsmouth, USA (DS) - Baxter, Bloomington, USA (DP)	06 August 2021
10.		SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 and 5 dose presentation (new manufacturing site)	07 May 2021 TBC after ongoing inspection
11.		COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™		Inactivated, produced in Vero cells	✓	✓	✓	Finalized 2 dose presentation	01 June 2021 30 September 2021
12.		Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	Process restarted, awaiting completion of rolling submission and CAPAs to last inspection-	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
13.		SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion inactivated Vero Cell	✓	✓	Rolling data started 06 July 2021	Ongoing	October 2021
14.		Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed
15.		Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021	Ongoing; inspection ongoing	TBC
16.		NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓	Rolling data starting in August 2021	Ongoing	TBC
17.		CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓		Rolling data started 30 July 2021	Ongoing	TBC
18.		NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓		Rolling data starting in August 2021	Ongoing	TBC
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	✓	Rolling data starting 20 September	Screened and communicated gaps. Data awaited	
20.		Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/COV050101	EMA	mNRA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for Q4 of 2021, at request of the applicant. Application withdrawn by manufacturer			
21.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	✓	Presubmission to be planned			

Vaccines							Guidance Document 20 October 2021		
	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	Vector State Research Centre of Virology and Biotechnology	EpiVacCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co Ltd  
2. Wuhan Institute of Biological Products Co Ltd  
\* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.  
\*\* Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made  
\*\*\* Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

.....

## COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

### AstraZeneca

Press Releases - No new digest announcements identified

### BioCubaFarma – Cuba

Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

### CanSinoBIO

News - [Website not responding at inquiry]

### Clover Biopharmaceuticals - China

News - No new digest announcements identified

## **Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

## **Gamaleya National Center**

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

## **IMBCAMS, China**

Home - No new digest announcements identified

## **Janssen/JNJ**

Press Releases

Oct 21, 2021 United States

[\*\*U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines\*\*](#)

Oct 20, 2021 United States

[\*\*Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA\*\*](#)

Oct 18, 2021 United States

[\*\*17 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to African Union Countries\*\*](#)

Oct 15, 2021 United States

[\*\*Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee\*\*](#)

## **Moderna**

Press Releases

October 21, 2021

[\*\*U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna's COVID-19 Vaccine\*\*](#)

October 20, 2021

[\*\*Moderna Announces FDA Authorization of a Booster Dose of Moderna's COVID-19 Vaccine in the U.S.\*\*](#)

October 14, 2021

[\*\*Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna's COVID-19 Vaccine in the U.S.\*\*](#)

October 14, 2021

[\*\*Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna's COVID-19 Vaccine for Low Income Countries in First Half of 2022\*\*](#)

## **Novavax**

Press Releases

[\*\*Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe\*\*](#) Oct 19, 2021

## **Pfizer**

Recent Press Releases

10.20.2021

[\*\*Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine\*\*](#)

10.20.2021

[\*\*Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer's PREVNAR 20™ \(Pneumococcal 20-valent Conjugate Vaccine\) in Adults\*\*](#)

## **Sanofi Pasteur**

Press Releases - No new digest announcements identified

## **Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

## **Sinopharm/WIBPBIBP**

News - No new digest announcements identified

## **Sinovac**

Press Releases - No new digest announcements identified

## **Vector State Research Centre of Virology and Biotechnology**

Home - No new digest announcements identified

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

## **GSK**

Press releases for media

[\*\*US Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes unanimously to recommend Shingrix for immunocompromised adults aged 19 and up\*\*](#)

20 October 2021

## **Merck**

News releases

[\*\*CDC ACIP Unanimously Votes to Provisionally Recommend Merck's VAXNEUVANCE™ \(Pneumococcal 15-valent Conjugate Vaccine\) in Series with PNEUMOVAX® 23\*\*](#)

## [\(Pneumococcal Vaccine Polyvalent\) as an Option for Pneumococcal Vaccination in Appropriate Adults](#)

October 29, 2021

## [Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults](#)

October 15, 2021

### **Novartis**

#### News

### [Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine](#)

Oct 21, 2021

:: At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia

:: New agreement follows earlier supply agreement for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland

### **SK Biosciences**

Press releases - No new digest announcements identified

.....  
.....

## [UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 23 Oct 2021](#)

***An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week's edition]***



25

vaccines approved for use by at least one national regulatory authority <sup>1</sup>



7

vaccines in WHO's Emergency Use Listing



19.5bn

doses secured globally



\$2-\$37

reported vaccine price range per dose



5.03bn

doses COVAX has secured, optioned, or received as donations



393.5M

doses shipped through COVAX to 144 countries

.....  
.....

### **Duke – Launch and Scale Speedometer** [The Race for Global COVID-19 Vaccine Equity](#)

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing

and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)



[See our COVID Vaccine Donations & Exports research](#)

### Overview of donations by top 10 donating countries

Bar chart is ordered by total number of doses pledged.

Donut charts are ordered by proportion of pledged donations shipped.

Country Category:  
Top 10 Donating Countries



Data updated on October 22nd 2021.

Duke | GLOBAL HEALTH  
Innovation Center





### Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard on Vaccine Equity** [accessed 23 Oct 2021]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)





.....  
.....  
.....

### ***Our World in Data***

#### **Coronavirus (COVID-19) Vaccinations** [Accessed 23 Oct 2021]

:: [48.4%](#) of the world population has received at least one dose of a COVID-19 vaccine.


:: [6.82 billion doses](#) have been administered globally, and [23.89 million](#) are now administered each day.

:: Only [3%](#) of people in low-income countries have received at least one dose.

## Share of the population fully vaccinated against COVID-19, Oct 22, 2021

Our World  
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data - Last updated 23 October 2021, 07:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY


Dec 27, 2020 Oct 22, 2021

## Share of the population fully vaccinated against COVID-19, Oct 22, 2021

Our World  
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

+ Add country



Source: Official data collated by Our World in Data - Last updated 23 October 2021, 07:00 (London time)

Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 27, 2020 Oct 22, 2021

.....  
.....

## **U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

.....

### **FDA**

#### **Vaccines and Related Biological Products Advisory Committee- FDA**

<https://www.fda.gov/advisory-committees/blood-vaccines-and-other-biologics/vaccines-and-related-biological-products-advisory-committee>

#### **[Vaccines and Related Biological Products Advisory Committee October 26, 2021 Meeting Announcement - 10/26/2021 - 10/26/2021](#)**

##### *Agenda*

...The committee will meet in open session to discuss Pfizer Inc.'s request to amend its Emergency Use Authorization (EUA) to allow for the use of the Pfizer-BioNTech COVID-19 vaccine in children 5 through 11 years of age.

.....

### **CDC**

#### **[CDC Expands Eligibility for COVID-19 Booster Shots](#)**

Thursday, October 21, 2021

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation for a booster shot of COVID-19 vaccines in certain populations. The [Food and Drug Administration's \(FDA\) authorization](#)[external icon](#) and CDC's recommendation for use are important steps forward as we work to stay ahead of the virus and keep Americans safe.

For individuals who received a Pfizer-BioNTech or Moderna COVID-19 vaccine, the following groups are eligible for a booster shot at 6 months or more after their initial series:

65 years and older

- Age 18+ who live in [long-term care settings](#)
- Age 18+ who have [underlying medical conditions](#)
- Age 18+ who work or live in [high-risk settings](#)

For the nearly 15 million people who got the Johnson & Johnson COVID-19 vaccine, booster shots are also recommended for those who are 18 and older and who were vaccinated two or more months ago.

There are now booster recommendations for all three available COVID-19 vaccines in the United States. Eligible individuals may choose which vaccine they receive as a booster dose. Some people may have a preference for the vaccine type that they originally received, and others may prefer to get a different booster. CDC's recommendations now allow for this type of mix and match dosing for booster shots...

### **CDC-ACIP**

#### **[Next ACIP Meetings](#)**

**:: November 2-3, 2021** - No agenda posted at 23 Oct 2021

.....

## **White House [U.S.]**

*Briefing Room – Selected Major COVID Announcements*

### **[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)**

October 22, 2021 • Press Briefings

### **[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)**

October 20, 2021 • Press Briefings

### **[FACT SHEET: Biden Administration Announces Update on Operational Planning for COVID-19 Vaccinations for Kids Ages 5-11](#)**

October 20, 2021 • Statements and Releases

...In anticipation of the FDA's independent advisory committee meeting on October 26 and the CDC's independent advisory committee meeting on November 2-3, today the Biden Administration is announcing a plan to ensure that, if a vaccine is authorized for children ages 5-11, it is quickly distributed and made conveniently and equitably available to families across the country. The start of a vaccination program for children ages 5-11 will depend on the independent FDA and CDC process and timeline, but our planning efforts mean that we will be ready to begin getting shots in arms in the days following a final CDC recommendation. These steps will be critical in ensuring that we are staying ahead of the virus by keeping kids and families safe, especially those at highest risk...

.....  
.....

## **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

### **European Medicines Agency**

*News & Press Releases*

#### **[News: EMA starts evaluating use of COVID-19 vaccine Comirnaty in children aged 5 to 11 \(new\)](#)**

CHMP, Last updated: 18/10/2021

#### **[News: New manufacturing sites and new formulation approved for COVID-19 vaccine from BioNTech/Pfizer \(new\)](#)**

CHMP, Last updated: 18/10/2021

.....

### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*Latest Updates*

*Publication*

#### **[COVID-19 surveillance guidance - Transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens](#)**

Technical report - 18 Oct 2021

.....



## European Centre for Disease Prevention and Control

### COVID-19 Vaccine Tracker

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
79.8%	74.6%

Accessed 23 Oct 2021

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

### European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

*Questions and answers* 22 October 2021

#### [Questions and answers on the list of 10 candidate COVID-19 therapeutics](#)

Vaccination is our primary tool to protect against infection, severe disease and hospitalisation and ultimately to put an end the pandemic.

*Press release* 22 October 2021

#### [European Health Union: Commission establishes portfolio of 10 most promising treatments for COVID-19](#)

Delivering on a key action from the EU Strategy on COVID-19 Therapeutics, the Commission is today establishing a portfolio of 10 potential COVID-19 therapeutics.

*Statement* 18 October 2021

#### [Statement by President von der Leyen on vaccine exports](#)

*President von der Leyen has made a statement about an important milestone in the delivery of COVID-19 vaccines to the world.*

**"We have reached an important milestone in the delivery of COVID-19 vaccines to the world. The European Union has exported over 1 billion vaccine doses worldwide, over the past ten months.** Vaccines produced in the EU have been shipped to more than 150 countries on all continents – from Japan to Turkey, from the UK to New Zealand, from South Africa to Brazil. We delivered around 87 million doses to low- and middle-income countries through COVAX. Very clearly, the European Union is the largest exporter of COVID-19 vaccines. We have always shared our vaccines fairly with the rest of the world. **We have exported as much as we delivered to EU citizens. Indeed, at least every second vaccine produced in Europe is exported.**

In parallel, the EU has enabled the vaccination of our citizens. And more than 75% of adults in the EU are now fully vaccinated. But we remained open to the world from the start and continued to export, even when vaccines were scarce at home. Because we knew that we will only beat COVID-19 if we fight it everywhere. And we will do more. Together with President Biden, we aim for a global

vaccination rate of 70% by next year. The EU-US Agenda for Beating the Global Pandemic will help us achieve that. The European Union is doing its part.

**On top of our exports, the EU will donate in the next months at least 500 million doses to the most vulnerable countries. But other countries need to step up, too.** I work closely with Prime Minister Draghi and President Biden to rally G20 leaders at the Rome Summit next week behind this ambitious goal: beating the global pandemic."

*Press release 18 October 2021*

### **The EU Digital COVID Certificate: a global standard with more than 591 million certificates**

Today, the Commission adopted a report on the EU Digital COVID Certificate and its implementation across the EU...The success of the EU Digital COVID Certificate system in figures:

:: EU Member States have issued more than 591 million EU Digital COVID Certificates

:: 43 countries are already connected to the [EU system](#): 27 EU Member States, 3 European Economic Area (EEA) countries, Switzerland, and 12 other countries and territories. **In total, the Commission was approached by 60 third countries interested in joining the EU system. Beyond the ones already connected, technical discussions are ongoing with 28 of these countries...**


.....  
.....

### **Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**

#### **Africa Vaccinated**

Vaccine Administered (Total)	(69.97% of supply)
Vaccine Administered (1 Dose)	(7.95% of population)
Vaccination Completed	(5.23% of population)

#### **Total of Supply Administered**



Vaccines received from COVAX

**49**  
Countries

Vaccines received bilaterally

**48**  
Countries

Vaccines received from AVATT

**32**  
Countries

Accesses 23 Oct 2021. Full scale, interactive dashboard available at:  
<https://africacdc.org/covid-19-vaccination/>

.....  
.....

## Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

#### [On information attacks against Sputnik V vaccine](#)

Press release, 21.10.2021

...Instead of attacking Sputnik, we urge Western mRNA vaccine producers to consider using the one-component Sputnik Light as a booster to help them achieve stronger immunity that lasts longer...

#### [Approval of mixing and matching of COVID booster shots by FDA is yet another confirmation of efficacy of vaccine cocktail approach pioneered by the Russian Sputnik V vaccine](#)

Press release, 21.10.2021

.....  
.....

## India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
23 October 2021, 08:00  
IST (GMT+5:30)

(↑↓ Status change since  
yesterday)

Active (0.51%)

173728 (2017↓)

Discharged (98.16%)

33532126 (17677↑)

Deaths (1.33%)

453708 (666↑)

COVID-19 Vaccination  
as on : 23 October  
2021, 08:00 IST  
(GMT+5:30)

Total Vaccination : 1,01,30,28,411 (68,48,417↑)

20.10.2021 [Guidelines for International Arrivals](#)

20.10.2021 [List of Countries to be referred to in context of 'Guidelines for international arrivals' dated 20th October 2021](#)

### Government of India – Press Information Bureau

[Latest Press Releases](#)

#### [COVID-19 Vaccination Update - Day 281](#)

Posted On: 23 OCT 2021 8:30PM by PIB Delhi



:: India's cumulative vaccination coverage crosses 102 crore

:: More than 70 lakh Vaccine doses administered today till 7 pm

India's COVID-19 vaccination coverage has crossed 102 Crore (1,02,03,34,409) today. More than 70 lakh (70,71,127) Vaccine Doses have been administered till 7 pm today. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

### **PIB'S BULLETIN ON COVID-1**

Posted On: 23 OCT 2021 7:51PM by PIB Delhi

- 101.30 crore vaccine doses have been administered so far under Nationwide Vaccination Drive
- 16,326 new cases in the last 24 hours
- Recovery Rate currently at 98.16%; Highest since March 2020
- 17,677 recoveries in the last 24 hours increases Total Recoveries to 3,35,32,126
- Active cases account for less than 1% of total cases, currently at 0.51%; Lowest since March 2020
- India's Active caseload stands at 1,73,728; lowest in 233 days
- Weekly Positivity Rate (1.24%) less than 2% for last 29 days
- Daily positivity rate (1.20%) less than 2% for last 19 days
- 59.84 crore Total Tests conducted so far

### **Indian Council for Medical Research (ICMR)**

<https://www.icmr.gov.in/media.html>

*Press Releases*

*No new digest content identified*

.....  
.....

### **China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

*See China CDC below for announcements.*

.....  
.....  
.....

### **Emergencies**

#### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

<https://polioeradication.org/polio-today/polio-now/this-week/>

#### **Polio this week as of 20 October 2021**

:: This week, the GPEI got the greenlight to resume house-to-house vaccination campaigns in Afghanistan which had been halted for over three years. Starting November 8, the campaigns will target over 3.3 million children in parts of the country that were previously inaccessible. [Read more](#) on this positive development.

:: For many of the women and men who spent their careers fighting polio, retirement offers not rest and relaxation, but a continuation of their life's work towards eradication. Across the Eastern

Mediterranean Region, once and forever polio fighters are inspiring the next generation of eradicators with their commitment to the cause, and belief in the benefits of a polio-free future. [Read more](#) in our latest feature story.

:: Following careful review of safety and genetic stability data from mass immunization campaigns conducted with the novel oral polio vaccine type 2 (nOPV2), the [Strategic Advisory Group of Experts on immunization \(SAGE\)](#) endorsed the transition to the next use phase for the vaccine. [Read more...](#)

***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

:: Nigeria: 37 cVDPV2 cases and 19 cVDPV2 positive environmental samples

:: Senegal: one cVDPV2 case

:: Somalia: one cVDPV2 case

.....

**[House-to-house polio vaccination set to recommence across Afghanistan in November](#)**

18 October 2021

*[See Milestones above for detail]*

**[Over 80 million reached as Africa trailblazes novel polio vaccine](#)**

22 October 2021

*[See Milestones above for detail]*

.....

.....

**WHO/OCHA Emergencies**

**Health emergencies list - WHO**

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

**[Afghanistan crisis](#)**

:: [House-to-house polio vaccination set to recommence across Afghanistan in November](#)

[18 October 2021](#)

**[Crisis in Northern Ethiopia](#)** *[Last apparent update: 5 Aug 2021]*

**[Ebola outbreak, Democratic Republic of the Congo, 2021](#)** *[Last apparent update: 17 Aug 2021]*

**[Ebola outbreak outbreak, N'Zerekore, Guinea, 2021](#)** *[Last apparent update: 17 Aug 2021]*

**[Coronavirus disease \(COVID-19\) pandemic](#)** *[See COVID above]*

**[Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020](#)**

*[Last apparent update: 17 Aug 2021]*

**[Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020](#)**

*[Last apparent update: 17 Aug 2021]*

[\*\*Ebola outbreak, Democratic Republic of the Congo, 2018\*\*](#) *[Last apparent update: 24 July 2018]*

[\*\*Yemen crisis\*\*](#) *[Last apparent update: 12 February 2021]*

[\*\*Syria crisis\*\*](#) *[Last apparent update: 18 June 2021]*

[\*\*Somalia crisis\*\*](#) *[Last apparent update: 24 March 2018]*

[\*\*Nigeria crisis\*\*](#)

:: Case study: Pilot implementation in Nigeria and Zambia, SBI COVID-19 data collection tool  
1 October 2021

[\*\*Ebola outbreak, Democratic Republic of the Congo, 2017\*\*](#) *[Last apparent update: 17 Aug 2021]*

[\*\*Zika virus disease outbreak, 2015-2016\*\*](#) *[Last apparent update: 24 Jan 2020]*

[\*\*Ebola outbreak: West Africa, 2014-2016\*\*](#) *[Last apparent update: 17 Aug 2021]*

[\*\*Iraq crisis\*\*](#) *[Last apparent update: 9 Jan 2008]*

[\*\*South Sudan crisis\*\*](#) *[Last apparent update: 23 Sep 2020]*

[\*\*Avian influenza A \(H7N9\) virus outbreak\*\*](#) *[Last apparent update: 13 September 2021]*

[\*\*Middle East respiratory syndrome \(MERS-CoV\) outbreak\*\*](#) *[Last apparent update: 8 July 2019]*

[\*\*Influenza A \(H1N1\) virus, 2009-2010 pandemic\*\*](#) *[Last apparent update: 10 Aug 2010]*

.....

[\*\*UN OCHA – Current Emergencies\*\*](#)

*Current Corporate Emergencies*

[\*\*Afghanistan: Weekly Humanitarian Update \(11 – 17 October 2021\)\*\*](#)

[\*\*Afghanistan: ICCT Real-Time Response Overview Situation Report \(21 October 2021\)\*\*](#)

*HIGHLIGHTS*

- Humanitarians seek US\$606 million as part of the Flash Appeal to provide prioritised multi-sectoral assistance to 11 million people in the four remaining months of 2021. Donors are urged to fast-track funding to mitigate against avoidable deaths, prevent displacement and reduce suffering. Donors are also urged to ensure that funding is flexible enough to adapt to the fast-changing conditions on the ground. As at 21 October, the Flash Appeal remained only 45 per cent funded, with a shortfall of some \$334 million.
- Humanitarians remain concerned about "conditional humanitarianism" or attempts to "leverage" humanitarian assistance for political purposes. Humanitarian action should never be conditioned to political, development, human rights or other non-humanitarian objectives. The conditioning of humanitarian aid is antithetical to the core principles of humanity, neutrality, impartiality and

independence, serves to erode respect for International Humanitarian Law and compromises humanitarian actors. Donors are urged to ensure transactions and other activities required for humanitarian operations are excluded from the scope of sanctions regimes to allow humanitarian activities to continue without impediment.

- Since 1 September 2021, partners have reached 39,383 children with community-based education activities, supported 53,983 people with standard NFIs assistance, provided 4 million people with food assistance, reached 790,000 people with primary healthcare, provided treatment for Acute Malnutrition to 85,623 children under five, supported 27,310 people with psychosocial support services, and assisted 165,000 drought-affected people with water trucking.
- The majority of activities during the reporting period have been carried out with existing funding. Humanitarians continue to urge for pledged funding to be rapidly translated into commitments to resource immediate response and preparedness activities.

### ***Northern Ethiopia***

#### **Ethiopia - Northern Ethiopia Humanitarian Update Situation Report, 21 Oct 2021**

##### ***HIGHLIGHTS***

- Two airstrikes on Mekelle killing three children and injuring 10 people, according to health officials. Another airstrike carried on 20 October, injuring a number of people.
- Between 7-13 October, only about 52,000 people reached with food or 1 per cent of the targeted population in Tigray, in which half of them received only one or two food items.
- Fuel is still not allowed to enter Tigray via Afar.  
The percentage of children identified with severe acute malnutrition in Tigray is rising on weekly basis and alarming at above two per cent.
- Partners reached more than 807,000 people with food since early August in Amhara Region, including nearly 97,000 people during the reporting period.

.....  
.....

#### **WHO & Regional Offices** [to 23 Oct 2021]

<https://www.who.int/>

22 October 2021

Departmental news

WHO, WIPO, WTO update information note on an integrated health, trade, IP response to COVID-19

21 October 2021

Departmental news

**Determination, innovation and adaptation can keep lymphatic filariasis elimination on track**

21 October 2021

News release

**WHO unveils action plan to address findings of Independent Commission on DRC SEA allegations**

21 October 2021

News release

**WHO and partners call for action to better protect health and care workers from COVID-19**

21 October 2021  
Departmental news

[Global TB Report app - Updated data in line with 2021 Global TB Report](#)

20 October 2021  
Departmental news

[NTDs: countries must adapt and innovate to mitigate COVID-19 disruptions](#)

20 October 2021  
Departmental news

[Health and Care Worker Deaths during COVID-19](#)

*[See Milestones above for detail]*

20 October 2021  
Departmental news

[WHO launches women's health chatbot with messaging on breast cancer](#)

19 October 2021  
Departmental news

[Scientists share data from first WHO-recommended malaria vaccine](#)

19 October 2021  
Departmental news

[WHO's 7 policy recommendations on building resilient health systems](#)

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: [Over 80 million reached as Africa trailblazes novel polio vaccine](#) 22 October 2021

### **WHO Region of the Americas PAHO**

*No new digest content identified*

### **WHO South-East Asia Region SEARO**

*No new digest content identified*

### **WHO European Region EURO**

:: [World Polio Day 2021 highlights progress and ongoing commitment to end polio everywhere](#) 21-10-2021

:: [Azerbaijan strengthens its health workforce to boost primary health care](#) 21-10-2021

:: [One billion COVID-19 vaccine doses administered in the WHO European Region – but risks for the unvaccinated leave no room for complacency](#) 21-10-2021

### **WHO Eastern Mediterranean Region EMRO**

:: House-to-house polio vaccination set to recommence across Afghanistan in November 18 October 2021

## **WHO Western Pacific Region**

*No new digest content identified*

.....

## **New WHO Publications [Selected]**

<https://www.who.int/publications/i>

*Selected Titles*

22 October 2021

### **[Integrated health, trade and IP approach to respond to the COVID-19 pandemic, 30 August 2021](#)**

*Overview*

The Trilateral Study is a result of the more than 10 years of trilateral cooperation between the Secretariats of WHO, WIPO and WTO. It seeks to strengthen the understanding of the ever-evolving interplay between the distinct policy domains of health, trade and intellectual property and their effect on innovation and access to health technologies, such as medicines, vaccines, diagnostics and medical devices.

21 October 2021

### **[Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac](#)**

21 October 2021

### **[Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of...](#)**

21 October 2021

### **[Coadministration of seasonal inactivated influenza and COVID-19 vaccines](#)**

*Overview*

Vaccination programmes against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. Administration of both vaccines during the same visit has potential advantages. This document presents the evidence related to coadministration of Covid-19 and influenza vaccines and the interim guidance.

19 October 2021

### **[Fourteenth report of the Strategic and Technical Advisory Group for Neglected Tropical Diseases \(STAG-NTDs\)](#)**

19 October 2021

### **[Infection prevention and control in primary care: a toolkit of resources](#)**

19 October 2021

### **[Building health systems resilience for universal health coverage and health security during the COVID-19...](#)**

19 October 2021

**WHO consultative meeting on science and technology foresight function for global health, 13 July 2021**

...The Global Health Foresight function in the Science Division aims to address the following areas:

- i. strengthen capabilities for the early identification of trends or advances in science and technology with notable impacts on public health;
- ii. generate country foresight and scenarios through structured, transparent processes that help identify how these trends might affect health and health systems in countries; and
- iii. develop strategic options to prepare future health systems to take advantage of opportunities, and proactively confront risks and challenges, and informing global health policy.

WHO's Science Division is working with various stakeholders, including international and regional organizations, technical experts, and other partnerships. It is important that the foresight function provides timely, useful, and actionable outputs relevant to all levels of the organization, member states, as well as the global community...

19 October 2021

**Mapping health systems' responsiveness to refugee and migrant health needs**

*Overview*

This mapping exercise reviews the ways in which countries with significant refugee and migrant populations have adapted their health-care systems and service delivery to meet the diverse needs of refugee and migrant populations. Understanding the models of care through which countries provide health services to refugees and migrants is critical to determining how the delivery of these services can be improved to ensure safe, effective and culturally sensitive care that also recognizes the strengths of refugee and migrant populations. The review identifies four models of care adopted by countries in response to migration trends and health needs of refugees and migrants: mainstream, specialized-focus, gateway and limited. It examines the strengths and weaknesses associated with each model. The application of these models in practice is described using case studies from 18 countries engaged in local integration or third-country resettlement of refugees and migrants.

19 October 2021

**An overview of infodemic management during COVID-19, January 2020–May 2021**

.....

.....

**CDC/ACIP [U.S.]** [to 23 Oct 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements*

**CDC Expands Eligibility for COVID-19 Booster Shots**

Thursday, October 21, 2021

*[See U.S. COVID above for detail]*

**CDC to Renew Advisory Committee to the Director**

Wednesday, October 20, 2021

The Advisory Committee to the Director of the Centers for Disease Control and Prevention (ACD), as authorized by federal law, is being re-established.



The ACD advises the CDC director, the Secretary of the Department of Health and Human Services (HHS), and the Assistant Secretary for Health on policy and broad strategies that will enable CDC to fulfill its mission of protecting the nation's health. It specifically recommends ways to prioritize CDC's activities, improve results, and address health disparities.

As an official federal advisory committee, the ACD also provides guidance to help CDC work more effectively with its various private and public sector constituents to make health protection a reality. Meetings are open to the public.

"As a physician scientist, I have always valued collaboration and diversity of thought," said CDC Director Rochelle P. Walensky, M.D., M.P.H. "For 57 years, this committee provided invaluable advice and counsel to prior CDC directors to help shape public health policy intended to protect people and save lives. I look forward to future collaborations with the committee."...

### **Next ACIP Meetings**

*No registration is required to watch the webcast.*

:: November 2-3, 2021 - No agenda posted at 23 Oct 2021

### **MMWR News Synopsis Friday, October 22, 2021**

*Selected Content*

:: HIV Infection and HIV-Associated Behaviors Among Persons Who Inject Drugs — 23 Metropolitan Statistical Areas, United States, 2018

:: Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021

### **Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 25 announcements/reports/data summaries.*

.....  
.....

**Africa CDC** [to 23 Oct 2021]

<http://www.africacdc.org/>

*News*

*No new digest content identified*

.....  
.....

**China CDC** <http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 23 Oct 2021]

<http://en.nhc.gov.cn/>

*News*

**Oct 23: Daily briefing on novel coronavirus cases in China**

On Oct 22, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 50 new cases of confirmed infections.

**National Medical Products Administration – PRC** [to 23 Oct 2021]

<http://english.nmpa.gov.cn/news.html>

*News*

**Over 2.238b COVID-19 vaccine doses administered on Chinese mainland**

2021-10-22

More than 2.238 billion doses of COVID-19 vaccines had been administered on the Chinese mainland as of Wednesday, data from the National Health Commission showed on Oct 21.

**CCDC Weekly - Weekly Reports: Current Volume (3)**

2021-10-22 / No. 43

[View PDF of this issue](#)

**Perspectives: Senior Research Scholars in China CDC's National Immunization Program**

China CDC's National Immunization Program's Senior Research Scholars Program (NIP-SRSP) is a program created to foster the professional development of early-to-mid-career immunization experts, strengthen knowledge exchange and cooperation between national and provincial/prefectural-level CDCs, and deepen scientific and programmatic capacity of the National Immunization Program and provincial/prefectural immunization programs. Initiated in September 2019, the NIP-SRSP recruits immunization professionals for a 12-to-18-month experience in Beijing who have worked at the Vice-Senior professional level or above and are recommended by their provincial/prefectural CDC supervisor and leadership. The first cohort of National Immunization Program Senior Research Scholars successfully completed the program and were recognized by CDC Director, Academician George F. Gao at a commencement ceremony on August 25, 2021...

.....  
.....  
.....

**Organization Announcements**

*Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

**Paul G. Allen Frontiers Group** [to 23 Oct 2021]

[https://alleninstitute.org/what-we-do/frontiers-group/new\\_s-press/](https://alleninstitute.org/what-we-do/frontiers-group/new_s-press/)

*News*

*No new digest content identified.*

**BARDA – U.S. Department of HHS** [to 23 Oct 2021]

<https://www.phe.gov/about/barda/Pages/default.aspx>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 23 Oct 2021]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

**[Bill & Melinda Gates Foundation Commits up to \\$120 Million to Accelerate Access to COVID-19 Drug for Lower-Income Countries, Calls on Other Donors to Mobilize Resources](#)**

*Financial commitment aims to secure dedicated, low-cost supply of molnupiravir, if the drug is authorized by regulators; builds on long-term efforts to increase access to tests, treatments, vaccines*  
Oct 19, 2021

... This commitment builds on the foundation's ongoing efforts, including \$1.9 billion in funding, since the start of the pandemic to increase access to COVID-19 vaccines, treatments, and tests by supporting R&D, regulatory work, at-risk manufacturing, and product delivery...

**Bill & Melinda Gates Medical Research Institute** [to 23 Oct 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*  
*No new digest content identified.*

**CARB-X** [to 23 Oct 2021]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 23 Oct 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: **[NEW] *Informed Consent: A Monthly Review – October 2021*** is now posted [here](#)

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 23 Oct 2021]

<http://cepi.net/>

*Latest News*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency** [to 23 Oct 2021]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 23 Oct 2021]

<https://dukeghic.org/>

*Our Blog*

*No new digest content identified.*

**EDCTP** [to 23 Oct 2021]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

18 October 2021

**[The Tenth EDCTP Forum has started](#)**

[Join](#) the Forum proceedings (registration only)

**Emory Vaccine Center** [to 23 Oct 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 23 Oct 2021]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified.*

**Fondation Merieux** [to 23 Oct 2021]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 23 Oct 2021]

<https://www.gavi.org/>

*News releases*

18 October 2021

**[First Portuguese COVAX doses reach Senegal](#)**

**GHIT Fund** [to 23 Oct 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*

*No new digest content identified.*

**Global Fund** [to 23 Oct 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 23 Oct 2021]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 23 Oct 2021]

<http://www.hillemanlabs.org/>

*Website reports "under maintenance" at inquiry*

**Human Vaccines Project** [to 23 Oct 2021]

<http://www.humanvaccinesproject.org/>

*News*

*Press Release*

Oct 22, 2021

[\*\*Lawrence Livermore National Laboratory joins Human Vaccines Project\*\*](#)

**IAVI** [to 23 Oct 2021]

<https://www.iavi.org/newsroom>

*Latest News*

October 20, 2021

[\*\*TB survivors from G20 countries call upon their leaders to invest \\$1 billion per year to develop new TB vaccines\*\*](#)

The call is endorsed by a global coalition advocating for a fully funded and resourced TB vaccine pipeline by 2023

October 20, 2021

In a direct address to their Heads of State and Government, a group of tuberculosis (TB) survivors from the G20 nations sent a letter to their political leaders as they prepare to gather at the G20 Summit in Rome, calling upon them to uphold their promise made at the United Nations High-Level Meeting (UN HLM) on TB in 2018 to develop new vaccines against TB. Written by a group of TB survivors and signed by TB survivors from each of the G20 countries and over 55 organizations around the world, the letter asks G20 leaders to secure an annual investment of at least US\$1 billion in TB vaccine research so that new TB vaccines are possible as early as 2025.

The letter is endorsed by the TB Vaccine Advocacy Roadmap (TB Vax ARM), a new global coalition of TB advocates and allied organizations spearheaded by IAVI, Results UK, and TAG. The coalition has come together to accelerate TB vaccine development by ensuring a fully funded and resourced TB vaccine pipeline by 2023, a requirement for delivering new TB vaccines in time to end the TB epidemic by 2030, the goal set at the UN HLM in 2018.

In the letter, TB survivors remind their leaders that even in the face of COVID-19, which killed 1.7 million people in 2020, TB remained the leading infectious cause of death in much of the world: "TB is a disease of inequity — over 90% of people who fall sick with TB live in developing and emerging economies. New TB vaccines could help protect us from the suffering we have experienced and save the precious lives and livelihoods of millions around the world from the leading infectious killer before COVID-19. We call on G20 countries to commit the resources needed to develop life-saving vaccines so that we can truly end TB during this decade," said Rhea Lobo, a TB survivor from India who helped lead this initiative...

October 18, 2021

### **Vaccines Security in Africa – Which Way Next?**

..."Vaccines Security in Africa – Which Way Next?" brought together researchers, policymakers, pharmaceutical/biotech companies, civil society organizations, and the media to discuss and advocate for pathways toward a sustainable vaccine development and manufacturing ecosystem backed with sustainable financing, strategic partnerships, innovative financing approaches, and domestic resource mobilization. Forum participants also highlighted opportunities to accelerate vaccine development and manufacturing in Africa. Speakers included representatives of Africa Centres for Disease Control and Prevention (CDC), AVMI, IAVI, WHO, and WHO Regional office for Africa (WHO/AFRO).

Keynote speaker Dr. Lindiwe Makubalo, assistant regional director, WHO/AFRO, stated that now is not the time to ask for political will, but rather political action, leadership, and practical support aimed at accelerating sustainable access to vaccines on the continent. She noted that COVID-19 presents new opportunities for action in domestic vaccine manufacturing and reiterated WHO's commitment to partnering with governments, policymakers, and regulators to support a sustainable market for locally produced vaccines....

### **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

### **ICRC [to 23 Oct 2021]**

<https://www.icrc.org/en/whats-new>

*Selected News Releases, Statements, Reports*

### **Statement on behalf of the 160 signatories to the Climate and Environment Charter for Humanitarian Organizations to the 26th UNFCCC COP**

"Today's climate and environmental crises threaten the survival of humanity. All dimensions of our lives are affected, from our physical and mental health to our food, water and economic security.

20-10-2021 | *Statement*

### **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 23 Oct 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

**Red Cross rushes relief as severe floods and landslides hit Nepal, India**

21/10/2021 | *Press release*

**Institut Pasteur** [to 23 Oct 2021]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**IOM / International Organization for Migration** [to 23 Oct 2021]

<http://www.iom.int/press-room/press-releases>

*News - Selected*

*News 19 Oct 2021*

**Djibouti Rolls Out COVID-19 Vaccinations for Migrants**

Djibouti – Migrants in Djibouti are being vaccinated against COVID-19 for the first time, as the International Organization for Migration (IOM) works with the Government to support the national immunization effort.

Since the start of the COVID-19 vaccine roll-out globally, IOM has been advocating for the inclusion of migrants and Djibouti is one of the first countries in the region to initiate a campaign for them. Around 70 migrants have received jabs since the vaccination drive began on 12 October and it will continue till at least the end of the year...

**ISC / International Science Council** [to 23 Oct 2021]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*News*

**Freedom and responsibility in the 21st century: a contemporary perspective on the free and responsible practice of science**

CFRS Draft Discussion Paper

September 2021 ;; 41 pages

The Paper is intended for a broad readership, including researchers, research managers, policymakers, science diplomats, and those in the private sector. As such, we invite you to identify a range of readers affiliated with your organization who can review the content of the draft Paper from these diverse perspectives.

#### 6. Conclusion

This Discussion Paper concludes on an optimistic note. Science is a unique human activity that, over time, has given us deep knowledge of ourselves and our place in the universe. Broadly defined, the sciences, including technology, the social sciences and humanities, have played vital roles in the human story in the 21st century. Researchers are key members of contemporary society. Their contribution to human wellbeing and to planetary health is maximized when they are allowed appropriate freedoms to meet their individual and collective responsibilities. The international scientific community,



governments, the public, and private research institutions should each have a clear sense of their freedoms and responsibilities, and a clear strategy to achieve the free and responsible practice of scientific research.

### **Draft Report on the ISC Strategy in the Intergovernmental System**

ISC/GA-2/DOC.17.1

October 2021 :: 13 pages

In March 2021, the ISC Chief Executive Officer Heide Hackmann invited Julia Marton-Lefèvre to chair a Steering Group to lead the development of a strategy for the ISC to engage with the intergovernmental system in order to enhance the impact of the Council and strengthen the voice of science in global policy processes...

**IVAC** [to 23 Oct 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 23 Oct 2021]

<http://www.ivi.int/>

*IVI News & Announcements*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 23 Oct 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

### **New Local Research Report Released on Improving COVID-19 Vaccination Equity for Latino Populations in Baltimore City**

October 20, 2021

### **Johns Hopkins Center for Health Security Contributing Scholar Tener Goodwin Veenema Elected to National Academy of Medicine**

October 18, 2021

### **New Report: Striving Toward Health Equity in COVID-19 - The Role of Pharmacies in a National Response**

October 18, 2021

**MSF/Médecins Sans Frontières** [to 23 Oct 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Tuberculosis*

### **Clinical trial results offer hope to DR-TB patients with short, effective treatment**

Press Release 20 Oct 2021

*Tuberculosis*

**EndTB clinical trial for multidrug-resistant TB completes enrolment**

Press Release 18 Oct 2021

**National Academy of Medicine** - USA [to 23 Oct 2021]

<https://nam.edu/programs/>

*Selected News/Programs/Events*

**National Academy of Medicine Elects 100 New Members**

October 18, 2021

The National Academy of Medicine (NAM) today announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service. "It is [...]

*[Excerpt]*

*Newly elected regular members of the National Academy of Medicine and their election citations include:*

**Kathrin U. Jansen, PhD**, senior vice president and head of vaccine research and development, Pfizer Inc. For leading the teams that produced three revolutionary vaccines: Gardasil, targeting human papillomavirus; Prevnar 13, targeting 13 strains of pneumococcus; and the Pfizer/BioNTech SARS-Covid-2 mRNA vaccine.

**Nancy Messonnier, MD**, executive director, pandemic prevention and health systems, Skoll Foundation. For her efforts in tackling the COVID-19 pandemic and building a global preparedness and response system to prevent future pandemics.

**Rochelle Paula Walensky, MD, MPH**, director, Centers for Disease Control and Prevention. For her work that motivated changes to HIV and COVID-19 guidelines, influenced public health practice, and provided rigorous evidence for decisions by the U.S. Congress, the World Health Organization, and Joint United Nations Programme on HIV/AIDS.

**National Academy of Medicine Announces Creation of David and Beatrix Hamburg Award for Advances in Biomedical Research and Clinical Medicine**

October 17, 2021

The National Academy of Medicine (NAM) has announced the creation of a new award — the David and Beatrix Hamburg Award for Advances in Biomedical Research and Clinical Medicine — to recognize creative and accomplished biomedical scientists who are advancing health and the human condition around the world.

**National Academy of Sciences** - USA [to 23 Oct 2021]

<http://www.nasonline.org/news-and-multimedia/>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 23 Oct 2021]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 23 Oct 2021]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

**COVID vaccine booster increases antibody responses, is protective in rhesus macaques**

October 21, 2021 — Different mRNA-1273 boosters are equally protective against variants.

**Interferon does not improve outcomes for hospitalized adults with COVID-19**

October 18, 2021 — Results of NIH clinical trial published today.

**PATH** [to 23 Oct 2021]

<https://www.path.org/media-center/>

*Press Releases*

**New HPV vaccine from Inovax receives WHO prequalification**

*This important milestone will provide countries with an additional option for HPV vaccination at an affordable price and will contribute to sustainable supply of HPV vaccine—allowing more girls to be reached with HPV vaccines.*

October 19, 2021 b

Cecolin®, a vaccine against human papillomavirus (HPV), has received prequalification by the World Health Organization (WHO). Cecolin is manufactured by Xiamen Inovax Biotech CO., LTD. (Inovax), a wholly owned subsidiary of Beijing Wantai Biological Pharmaceutical Co., LTD. (Wantai), and is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. Countries facing barriers to national introduction or expanding their HPV vaccine program to the full cohort due to price or supply constraints will now have another option for affordable, sustainable access....

Prior to Cecolin's licensure in China, PATH provided Inovax with technical assistance for the WHO prequalification process. Activities included improving the quality management system, establishing a post-marketing pharmacovigilance system, and collecting information on regulatory requirements for registration of vaccines in Gavi countries...

Prior to Cecolin's licensure in China, PATH provided Inovax with technical assistance for the WHO prequalification process. Activities included improving the quality management system, establishing a post-marketing pharmacovigilance system, and collecting information on regulatory requirements for registration of vaccines in Gavi countries.

**Sabin Vaccine Institute** [to 23 Oct 2021]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

**Sabin Vaccine Institute Receives Additional \$34.5 Million from BARDA for Further Development of Ebola Sudan and Marburg Vaccines**

Thursday, October 21, 2021

The Sabin Vaccine Institute (Sabin) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the third contract option, valued at \$34.5 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials...

**UNAIDS** [to 23 Oct 2021]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

21 October 2021

**[A Dose of Reality: How rich countries and pharmaceutical corporations are breaking their vaccine promises](#)**

19 October 2021

**[Strengthening the response of health systems to pandemics in the Commonwealth of Independent States](#)**

18 October 2021

**["Realizing the right to reproductive health and the future starts with sexual education"](#)**

18 October 2021

**[Capitalizing on experiences to improve HIV care for key populations in western Africa](#)**

18 October 2021

**[Upper-middle-income countries pay more for HIV medicines, but price reductions can be achieved](#)**

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 23 Oct 2021]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected News Releases, Announcements*

*No new digest content identified.*

**UNICEF** [to 23 Oct 2021]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*Press release 10/19/2021*

**[UNICEF medical supplies arrive in Kabul to treat rising cases of acute watery diarrhoea in Afghanistan](#)**

*Press release 10/18/2021*

**[House-to-house polio vaccination set to recommence across Afghanistan in November](#)**

*[See Milestones above for detail]*

**Unitaid** [to 23 Oct 2021]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccine Equity Cooperative [nee Initiative]** [to 23 Oct 2021]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 23 Oct 2021]

<https://www.vaccineacceptance.org/>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 23 Oct 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

**[Coronavirus global impact](#)**

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 23 Oct 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**[Vaccine Update Newsletter - September 2021](#)**

*Vaccine Update* is our monthly email newsletter that will keep you up to date on current vaccine-related issues.

**Wellcome Trust** [to 23 Oct 2021]

<https://wellcome.ac.uk/news>

*News and reports*

*News*

**[Wellcome appoints first climate director](#)**

18 October 2021

Alan Dangour, an expert in the impact of climate change on food systems, is to join Wellcome as our first director of climate and health.

**The Wistar Institute** [to 23 Oct 2021]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 23 Oct 2021]

<https://www.wfpha.org/>

*Latest News*

**[Pandemic Treaty: A Public Health View](#)**

## *News*

Oct 20, 2021

The World Health Assembly (WHA) will meet in a special session from 29 November – 1 December 2021 to consider the benefits of developing a World Health Organisation (WHO) convention, agreement or another international instrument on pandemic preparedness and response.

As countries are preparing for discussions at the special session, the Global Health Centre (GHC) at the Graduate Institute of International and Development Studies in Geneva offers to support governments and other actors with knowledge and evidence in the process. This is part of a broader project exploring options and benefits of a pandemic treaty, which includes also, inter alia, a series of policy papers by lead experts, dialogue with diplomats, policymakers, and stakeholders.

Against this backdrop, the WFPHA and the GHC called for a meeting for WFPHA members and all allied partners on options and benefits of a pandemic treaty. The meeting took place in a virtual format on 20 October 2021.

The meeting was comprised of two sections: An introductory presentation on key global and public health/civil society aspects of the subject matter by the GHC and the WFPHA, followed by a Q&A session. The second section was an informal exchange and discussion between participants under the Chatham House rule. The knowledge gained, and the informal dialogues convened can contribute to WFPHA's members and partners' cooperation with governmental and non-state actors on the subject matter and may lead to a follow-up statement.

During the meeting, a Guide on key aspects and frequently asked questions on a pandemic treaty developed at the GHC was made available to the registered participants.

**World Bank** [to 23 Oct 2021]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

### **Food Security and COVID-19**

Oct. 21, 2021 – An increasing number of countries are facing growing levels of acute food insecurity, reversing years of development gains. Even before COVID-19 reduced incomes and disrupted supply chains...

Date: October 21, 2021 Type: Brief

### **Rolling out COVID-19 Vaccines in Malawi Amid Hesitancy and Supply Challenges**

LILONGWE, October 19, 2021— One early morning in August, Priscilla Pahuwa walked into St. Montfort hospital in Nchalo, Chikwawa District, to get the COVID-19 vaccine. She was eager to receive the vaccine...

Date: October 19, 2021 Type: Feature Story

### **Arrival of 4.73 Million Doses of WB-funded Vaccines Boosts Drive Against COVID-19 in the Philippines**

MANILA, October 19, 2021 — To date, 4.73 million doses of vaccines out of 13 million doses procured by the country under the Philippines US\$500 million COVID-19 Emergency Response Project Additional Financing...

Date: October 19, 2021 Type: Press Release

**World Customs Organization – WCO** [to 23 Oct 2021]

<http://www.wcoomd.org/>

*Latest News – Selected Items*  
*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 23 Oct 2021]

<https://www.oie.int/en/media/news/>

*Press Releases, Statements*

**Building resilience against agro-terrorism and agro-crime**

13 October 2021

The World Organisation for Animal Health (OIE), the Food and Agriculture Organization of the United Nations (FAO), and the International Criminal Police Organization (INTERPOL) are partners in an international project to build sustainable global resilience against animal health emergencies caused by agro-terrorism and agro-crime.

Established in October 2018, the project aims to foster coordination at the national, regional, and international levels. It focuses on regions where the previous work of the three organisations has identified gaps in various aspects of emergency management that may make countries vulnerable to agro-crime and agro-terrorism. The target regions include the Middle East, North Africa and South-East Asia. However, while the project concentrates on these regions, its outputs will be relevant to all countries worldwide.

To ensure that the resulting capacity building is fit for purpose, the project is currently assessing the global situation for emergency management by identifying areas that are vulnerable to agro-crime and agro-terrorism; understanding the cost-effectiveness of investing in preparedness; and using OIE, FAO and INTERPOL tools to examine emergency management, including the relationship between the law enforcement and veterinary sectors...

**WTO - World Trade Organisation** [to 23 Oct 2021]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events*

**Coordinated global response key to MSMEs' post-pandemic economic recovery — DDG Zhang**

22 October 2021

Deputy Director-General Xiangchen Zhang highlighted the importance of targeted policies and a coordinated global response to mitigate the impact of the COVID-19 pandemic on micro, small and medium-sized enterprises (MSMEs). DDG Zhang was speaking at a workshop organized by the WTO Chairs Programme at the University of Mauritius on 22 October. Noting that "MSMEs are the backbone of many economies", he called on WTO members to "foster a transparent, inclusive, non-discriminatory, and predictable global trade environment that supports and enhances MSMEs' involvement in international trade." His remarks are below.

**WHO, WIPO, WTO update information note on integrated health, trade, IP response to COVID-19**

22 October 2021

On 22 October 2021, the World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the WTO launched an update of the extract "Integrated health, trade and IP approach to respond to the COVID-19 pandemic". This extract, from the second edition of the Trilateral Study Promoting Access to Medical Technologies and Innovation, maps the challenges posed by the

COVID-19 pandemic in relation to the integrated health, trade and intellectual property policy framework set out in the Trilateral Study.

.....

**ARM [Alliance for Regenerative Medicine]** [to 23 Oct 2021]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 23 Oct 2021]

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 23 Oct 2021]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 23 Oct 2021]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 23 Oct 2021]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**As COVID-19 vaccine output estimated to reach over 12 billion by year end and 24**

19 October 2021

- This month, COVID-19 vaccine manufacturing output will pass the 9.3 billion dose mark. The biopharmaceutical industry renews its May commitment to the G20 to collaborate with governments to support effective solutions to urgently address vaccine equity.
- At current production rates, swiftly rolling out vaccines to those who still need them looks achievable, if the political will, planning and collective action efforts are redoubled. The G20 can play a critical role in focusing political attention on ramping up dose sharing, addressing bottlenecks in the supply chain and supporting country preparedness.
- With COVID-19 vaccine supplies on track to outstrip global demand and voluntary collaborations with innovative vaccine manufacturers set to change Africa's vaccine manufacturing landscape in years to come, initiatives such as the proposed Intellectual Property TRIPS waiver are a distraction. All efforts should be directed towards advancing vaccinations.

**International Generic and Biosimilar Medicines Association [IGBA]**



<https://www.igbamedicines.org/>

*News*

**[IGBA Biosimilars Committee White Paper: A Biosimilar medicines Access Policy Blueprint \(October 2021\)](#)**

***Effective Strategies to Advance Access to Biologic Therapies for Non-Communicable Diseases***

October 2021 :: 32 pages PDF: <https://www.globalbiosimilarsweek.org/2021/doc/A-Biosimilar-medicines-Access-Policy-Blueprint-IGBA.pdf>

**International Alliance of Patients' Organizations – IAPO** [to 23 Oct 2021]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

**[Registration is now open for the 3rd Asia-Pacific Patients Congress \(APPC 2021\)](#)**

Monday, 18 October 2021

We are delighted to invite you to register for our upcoming virtual 3rd Asia-Pacific Patients Congress (APPC 2021) taking place on 16 -17 November 2021. This flagship event will once again bring together our regional membership of expert patients with a variety of high-level healthcare stakeholders...

*Sample Program Element [Day 2]*

**Meaningful patient engagement in co-creation in medicines and health devices R&D - moving from tokenism to meaningful engagement at all levels**

The COVID-19 'fast-track' vaccines development process has educated many patients on how clinical trials are conducted. Asia-Pacific patients are now more aware of the opportunities and challenges faced by R&D teams. This session will invite experts to showcase how meaningful patient engagement in clinical R&D settings is undertaken now. We will also invite PPI Japan EUPATI's national platform in Japan to show how meaningful patient engagement in clinical trials is conducted in Japan.

**PhRMA** [to 23 Oct 2021]

<http://www.phrma.org/>

*Latest News [Selected]*

**[In Honor of Visionary Leader, PhRMA Announces the Kenneth C. Frazier PhRMA Scholars Program](#)**

WASHINGTON, D.C. (October 21, 2021) – In honor of retiring PhRMA board member and visionary industry leader Ken Frazier, PhRMA today announced The Kenneth C. Frazier PhRMA Scholars Program to provide college scholarships to academically high achieving, low-income students in Washington, D.C. and in Ken's hometown of Philadelphia, Pennsylvania. Frazier, currently executive chairman of Merck & Co, Inc., has served on the PhRMA board since 2011...

\*

\*

\*

\*

***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some

editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 12, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

*Article*

#### **Deliberation on Childhood Vaccination in Canada: Public Input on Ethical Trade-Offs in Vaccination Policy**

Kieran C. O'Doherty, Sara Crann, Lucie Marisa Bucci, Michael M. Burgess, Apurv Chauhan, Maya J. Goldenberg, C. Meghan McMurtry, Jessica White & Donald J. Willison

Pages: 253-265

Published online: 30 Jul 2021

We conclude that conducting deliberative democratic processes on topics that are polarizing and controversial is viable and should be further developed and implemented to support democratically legitimate and trustworthy policy about childhood vaccination.

### **AMA Journal of Ethics**

Volume 23, Number 10: E757-831

<https://journalofethics.ama-assn.org/issue/palliative-surgery>

#### ***Palliative Surgery***

Palliative care is not just for dying patients. In fact, dying patients are living patients, and all patients deserve palliation. Contrary to popular belief among many patients and clinicians, palliative interventions can be invasive and include not only medical, but surgical care. In any case, palliative care should be defined by intention: partnering clinicians, patients, and their loved ones aim neither to cure disease nor to prolong life, but to improve the quality of a patient's life at any needed time. Quality of life is motivated by goal-elucidating conversation, counseling, and symptom management-directed intervention. This issue investigates surgical palliation specifically, with sharp focus on intention formation and trust preservation.

### **American Journal of Infection Control**

October 2021 Volume 49 Issue 10 p1215-1342

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

September 2021 Volume 61 Issue 3 p311-464

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

October 2021 111(10)  
<http://ajph.aphapublications.org/toc/ajph/current>  
[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 105 (2021): Issue 2 (Aug 2021)  
<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>  
[Reviewed earlier]

### **Annals of Internal Medicine**

October 2021 Volume 174, Issue 10  
<http://annals.org/aim/issue>

*Original Research*

#### **[Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States - A Retrospective Cohort Study](#)**

FREE

Hemalkumar B. Mehta, MS, PhD, Huijun An, MS, Kathleen M. Andersen, MSc, Omar Mansour, MHS, ... [et al.](#)

Pages:1395–1403

#### **[SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting](#)**

FREE

Adeel A. Butt, MBBS, MS, Saad B. Omer, MBBS, MPH, PhD, Peng Yan, MS, Obaid S. Shaikh, MD, ... [et al.](#)

Pages:1404–1408

*Position Papers*

#### **[Financial Profit in Medicine: A Position Paper From the American College of Physicians](#)**

FREE

Ryan Crowley, BSJ, Omar Atiq, MD, David Hilden, MD,

Pages:1447–1449

*Editorials*

#### **[Thrombosis After Vaccination With Messenger RNA–1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome?](#)**

FREE

Allyson M. Pishko, MD, Adam Cuker, MD, MS

Pages:1468–1469

### **Artificial Intelligence – An International Journal**

Volume 299 October 2021  
<https://www.sciencedirect.com/journal/artificial-intelligence/vol/299/suppl/C>  
[Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 23 Oct 2021)

[No new digest content identified]

### **BMJ Global Health**

September 2021 - Volume 6 - 9

<https://gh.bmj.com/content/6/9>

[Reviewed earlier]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 23 Oct 2021)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 23 Oct 2021)

#### **[The incidence and mortality of yellow fever in Africa: a systematic review and meta-analysis](#)**

*Understanding the occurrence of yellow fever epidemics is critical for targeted interventions and control efforts to reduce the burden of disease. We assessed data on the yellow fever incidence and mortality r...*

Authors: Akuoma U. Nwaiwu, Alfred Musekiwa, Jacques L. Tamuzi, Evanson Z. Sambala and Peter S. Nyasulu

Citation: BMC Infectious Diseases 2021 21:1089

Content type: Research

Published on: 23 October 2021

#### **[Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region](#)**

*Invasive meningococcal disease (IMD) represents a global health burden. However, its epidemiology in the Eastern Mediterranean (EM) and North Africa (NA) regions is currently not well understood. This review h...*

Authors: Alp Giray Dogu, Anouk M. Oordt-Speets, Femke van Kessel-de Bruijn, Mehmet Ceyhan and Amine Amiche

Citation: BMC Infectious Diseases 2021 21:1088

Content type: Research

Published on: 22 October 2021

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 23 Oct 2021)

## **Uses of equipoise in discussions of the ethics of randomized controlled trials of COVID-19 therapies**

*Early in the COVID-19 pandemic, the urgent need to discover effective therapies for COVID-19 prompted questions about the ethical problem of randomization along with its widely accepted solution: equipoise. In...*

Authors: Hayden P. Nix and Charles Weijer

Citation: BMC Medical Ethics 2021 22:143

Content type: Research

Published on: 21 October 2021

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 23 Oct 2021)

## **Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England**

*The BNT162b2 mRNA vaccine has been shown to be effective at preventing serious COVID-19 events in clinical trials. There is less evidence on effectiveness in real-world settings, especially for older people. H...*

Authors: Thomas F. D. Mason, Matt Whitston, Jack Hodgson, Ruth E. Watkinson, Yiu-Shing Lau, Omnia Abdulrazeg and Matt Sutton

Citation: BMC Medicine 2021 19:275

Content type: Research article

Published on: 18 October 2021

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 23 Oct 2021)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 23 Oct 2021)

[No new digest content identified]

## **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 23 Oct 2021)

[No new digest content identified]

## **BMJ Evidence-Based Medicine**

October 2021 - Volume 26 - 5

<https://ebm.bmj.com/content/26/5>

[Reviewed earlier]

**BMJ Open**

October 2021 - Volume 11 - 10

<https://bmjopen.bmj.com/content/11/10>

[Reviewed earlier]

**Bulletin of the World Health Organization**

Volume 99(10); 2021 Oct 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/390889/>

[Reviewed earlier]

**Cell**

Oct 14, 2021 Volume 184 Issue 21 p5261-5496

<https://www.cell.com/cell/current>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 47, Issue 6 Pages: 733-885 November 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

**Clinical Pharmacology & Therapeutics**

Volume 110, Issue 4 Pages: 827-1135 October 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

**Clinical Therapeutics**

June 2021 Volume 43 Issue 6 p917-1134

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 18 Issue 5, October 2021

<https://journals.sagepub.com/toc/ctja/18/5>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 23 Oct 2021]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 108 September 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/108/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 4, Issue 4 / August 2021

<https://www.liebertpub.com/toc/crispr/4/4>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

October 2021 - Volume 34 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

*TROPICAL AND TRAVEL-ASSOCIATED DISEASES*

Edited by Christina M. Coyle

[Reviewed earlier]

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 21, Issue 3 Pages: 97-148 September 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 31, Issue 7, 2021

<http://www.tandfonline.com/toc/cdip20/current>

***The Private Sector in the Development Landscape.***

Guest Editors: Jason Hart, Jo-Anna Russon & Jessica Sklair

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 45, Issue 4 Pages: 739-995 October 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

### **EMBO Reports**

Volume 22 Issue 9 6 September 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 27, Number 9—September 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 36 September 2021

<https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 43, Issue 5 Pages: 1-44 September–October 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

### **Ethics & International Affairs**

Fall 2021 (35.3) | October 2021

<https://www.ethicsandinternationalaffairs.org/2021/fall-2021-35-3/>

The editors of Ethics & International Affairs are pleased to present the Fall 2021 issue of the journal! The highlight of this issue is a book symposium organized by Peter Balint on Ned Dobos's Ethics, Security, and the War Machine, featuring contributions by Peter Balint; Neta C. Crawford; C. A. J.



Coady; Ned Dobos; Cécile Fabre; Christopher J. Finlay; David Rodin; and Cheyney Ryan. Additionally, the issue includes a feature article by Philipp Gisbertz-Astolfi on the reduced legal equality of combatants in war and an essay by Hendrik Schopmans and Jelena Cupać on ethical AI, gender equality, and illiberal backlash politics. It also contains a review essay by Andreas Papamichail on the global politics of health security, and a book review by Claire Finkelstein.

#### *REVIEW ESSAY*

#### **The Global Politics of Health Security before, during, and after COVID-19**

Andreas Papamichail

##### *Abstract*

The COVID-19 pandemic has been shaped by preexisting political, social, and economic relations and governance structures, and will remold these structures going forward. This review essay considers three books on global health politics written by Simon Rushton, Clare Wenham, and Jeremy Youde. Here, I explore what these books collectively and individually can tell us about these preexisting dynamics, the events of the first eighteen months of the COVID-19 pandemic, and possible future directions in the politics of global health. I argue that they provide a firm basis for understanding the inequitable burdens of the pandemic, while juxtaposing these inequities against the narratives of shared vulnerability that sit at the heart of the global health security regime. They also help us make sense of the surveillance, detection, containment, and response mechanisms we have seen during the pandemic; the failures to address the systemic dynamics that drive disease outbreaks; and the national and international politics that have shaped the pandemic response. However, COVID-19 has also vividly and brutally demonstrated how global health hierarchies, racism, border politics, and neoliberal forms of knowledge production have led to a stratified burden of the pandemic. These areas are less apparent in the three books, but ought to be situated front and center in future critical scholarship on global health security.

#### **Ethics, Medicine and Public Health**

September 2021

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/18/suppl/C>

[Reviewed earlier]

#### **The European Journal of Public Health**

SUPPLEMENT - Volume 31, Issue Supplement\_1, July 2021

[https://academic.oup.com/eurpub/issue/31/Supplement\\_1](https://academic.oup.com/eurpub/issue/31/Supplement_1)

#### ***Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions***

Mental illness represents an enormous personal, social and societal burden for European citizens<sup>1</sup> calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,<sup>2</sup> and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth'<sup>3</sup> and 'm-Health'<sup>4</sup>) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders<sup>5,6</sup> and meta-analyses show effect sizes similar to face-to-face interventions.<sup>7</sup>

#### **Expert Review of Vaccines**

Vol 20 (9) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 23 Oct 2021]

[No new digest content identified]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 23 Oct 2021]

[No new digest content identified]

### **Global Health Action**

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 9, No. 3 September 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

### **Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 23 Oct 2021]

[No new digest content identified]

### **Global Public Health**

Volume 16, Issue 11 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 23 Oct 2021]

**Comparing COVID-19 physical distancing policies: results from a physical distancing intensity coding framework for Botswana, India, Jamaica, Mozambique, Namibia, Ukraine, and the United States**

*Understanding the differences in timing and composition of physical distancing policies is important to evaluate the early global response to COVID-19. A physical distancing intensity monitoring framework comprising 16 domains was recently published to compare physical distancing approaches across 12 U.S. States. We applied this framework to a diverse set of low and middle-income countries (LMICs) (Botswana, India, Jamaica, Mozambique, Namibia, and Ukraine) to test the appropriateness of this framework in the global context and to compare the policy responses in these LMICs with a sample of U.S. States during the first 100-days of the pandemic.*

Authors: Jeff Lane, Arianna Rubin Means, Kevin Bardosh, Anna Shapoval, Ferruccio Vio, Clive Anderson, Anya Cushnie, Norbert Forster, Jenny Ledikwe, Gabrielle O'Malley, Shreshth Mawandia, Anwar Parvez, Lucy Perrone and Florindo Mudender

Content type: Research

23 October 2021

**Health and Human Rights**

Volume 23, Issue 1, June 2021

<https://www.hhrjournal.org/volume-23-issue-1-june-2021/>

[Reviewed earlier]

**Health Economics, Policy and Law**

Volume 16 - Issue 4 - October 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

**Health Policy and Planning**

Volume 36, Issue 8, October 2021

<https://academic.oup.com/heapol/issue/36/8>

[Reviewed earlier]

**Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 23 Oct 2021]

[No new digest content identified]

**Human Gene Therapy**

Volume 32, Issue 19-20 / October 2021

<https://www.liebertpub.com/toc/hum/32/19-20>

[New issue; No digest content identified]

## **Humanitarian Exchange Magazine**

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

### **Localisation and local humanitarian action**

*by HPN October 2020*

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 10, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

## **Immunity** **[NEW JOURNAL ADDED]**

Oct 12, 2021 Volume 54 Issue 10 p2169-2436

<https://www.cell.com/immunity/current>

[Reviewed earlier]

## **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 23 Oct 2021]

[No new digest content identified]

## **Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>

[Accessed 23 Oct 2021]

### **Roll-out of vaccination against COVID-19 pandemic**

*With the rebound of coronavirus disease 2019 (COVID-19) epidemic in some countries with high vaccination rate, many concerns on vaccine efficacy have emerged. For example, are the current vaccines ineffective against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) variants? What's the status of breakthrough infection? To what extent are non-pharmacological interventions*

*(NPIs) lifted after high vaccination rate? To clarify these questions, we summarized important findings based on literature and Chinese experience.*

Authors: Xiao-Feng Liang, Guan-Hao He, Wen-Jun Ma and Jian-Peng Xiao

Citation: Infectious Diseases of Poverty 2021 10:125

Content type: Commentary

Published on: 18 October 2021

### **International Health**

Volume 13, Issue 5, September 2021

<https://academic.oup.com/inthealth/issue/13/5>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol 8, No 10 (2021) October 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/81>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 50, Issue 4, August 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Infectious Diseases**

October 2021 Volume 111 p1-362

<https://www.ijidonline.com/current>

[Reviewed earlier]

### **JAMA**

October 19, 2021, Vol 326, No. 15, Pages 1463-1544

<https://jamanetwork.com/journals/jama/currentissue>

*Research Letter*

**[Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273](#)**

Deborah Steensels, PharmD, PhD; Noella Pierlet, MSc; Joris Penders, MD, PhD; et al.

*free access has active quiz*

JAMA. 2021;326(15):1533-1535. doi:10.1001/jama.2021.15125

This study compares the immune responses to the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines in health care workers in Belgium.

**JAMA Network**

**[COVID-19 Update October 23, 2021](#)**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

**JAMA Pediatrics**

October 2021, Vol 175, No. 10, Pages 990-1088

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

**JBI Evidence Synthesis**

October 2021 - Volume 19 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

October 2021 Volume 69 Issue 4 p533-682

<https://www.jahonline.org/current>

[Reviewed earlier]

**Journal of Artificial Intelligence Research**

Vol. 72 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 46, issue 5, October 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-5>

[Reviewed earlier]

**Journal of Development Economics**

Volume 153 November 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/153/suppl/C>

[New issue; No digest content identified]

**Journal of Empirical Research on Human Research Ethics**

Volume 16 Issue 4, October 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

September 2021 - Volume 75 - 9

<https://jech.bmj.com/content/75/9>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 14, Issue 3 Pages: 171-256 September 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 17, Issue 1, 2021

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 32, Number 3, August 2021

<https://muse.jhu.edu/issue/45771>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 23, issue 5, October 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-5>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 224, Issue 6, 15 September 2021

<https://academic.oup.com/jid/issue/224/6>  
[Reviewed earlier]

**Journal of Medical Ethics**

October 2021 - Volume 47 - 10  
<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 8, Issue 4 (2021)  
<https://digitalrepository.aurorahealthcare.org/jpcrr/>  
***Cancer Screening***

**Journal of Pediatrics**

October 2021 Volume 237 p1-324  
<http://www.jpeds.com/current>  
[New issue; No digest content identified]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>  
[Accessed 23 Oct 2021]  
[No new digest content identified]

**Journal of Public Health Management & Practice**

September/October 2021 - Volume 27 - Issue 5  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 42, issue 3, September 2021  
<https://link.springer.com/journal/41271/volumes-and-issues/42-3>  
[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)  
<https://ir.library.louisville.edu/rgh/>  
[Reviewed earlier]

**Journal of the Royal Society – Interface**

October 2021 Volume 18 Issue 183



<https://royalsocietypublishing.org/toc/rsif/current>  
[Reviewed earlier]

### **Journal of Travel Medicine**

Volume 28, Issue 7, October 2021  
<https://academic.oup.com/jtm/issue>  
[Reviewed earlier]

### **Journal of Virology**

Volume 95 • Number 21 • October 2021  
<http://jvi.asm.org/content/current>  
[Reviewed earlier]

### **The Lancet**

Oct 23, 2021 Volume 398 Number 10310 p1461-1540  
<https://www.thelancet.com/journals/lancet/issue/current>  
[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Oct 2021 Volume 5 Number 10 p681-766, e39-e43  
<https://www.thelancet.com/journals/lanchi/issue/current>  
[Reviewed earlier]

### **Lancet Digital Health**

Oct 2021 Volume 3 Number 10 e612-e683  
<https://www.thelancet.com/journals/landig/issue/current>  
[Reviewed earlier]

### **Lancet Global Health**

Oct 2021 Volume 9 Number 10 e1336-e1473  
<https://www.thelancet.com/journals/langlo/issue/current>  
[Reviewed earlier]

### **Lancet Infectious Diseases**

Oct 2021 Volume 21 Number 10 p1333-1470, e302-e340  
<https://www.thelancet.com/journals/laninf/issue/current>  
[Reviewed earlier]

### **Lancet Public Health**

Oct 2021 Volume 6 Number 10 e696-e779

<https://www.thelancet.com/journals/lanpub/issue/current>  
[Reviewed earlier]

### **Lancet Respiratory Medicine**

Oct 2021 Volume 9 Number 10 p1077-1202, e96-e103  
<https://www.thelancet.com/journals/lanres/issue/current>  
[Reviewed earlier]

### **Maternal and Child Health Journal**

Volume 25, issue 10, October 2021  
<https://link.springer.com/journal/10995/volumes-and-issues/25-10>  
[Reviewed earlier]

### **Medical Decision Making (MDM)**

Volume 41 Issue 7, October 2021  
<http://mdm.sagepub.com/content/current>  
[Reviewed earlier]

### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*  
Volume 99, Issue 3 Pages: 601-852 September 2021  
<https://onlinelibrary.wiley.com/toc/14680009/current>  
[Reviewed earlier]

### **Nature**

Volume 598 Issue 7881, 21 October 2021  
<https://www.nature.com/nature/volumes/598/issues/7881>  
*News & Views* | 06 October 2021

#### **[A step towards therapeutics for dengue](#)**

Finding a treatment for dengue, the most prevalent mosquito-borne viral disease in humans, has been difficult. A compound called JNJ-A07 displays promising activity against dengue virus in mouse models of infection.

Scott B. Biering, Eva Harris

### **Nature Biotechnology**

Volume 39 Issue 10, October 2021  
<https://www.nature.com/nbt/volumes/39/issues/10>  
[Reviewed earlier]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 23 Oct 2021)  
[No new digest content identified]

### **Nature Genetics**

Volume 53 Issue 10, October 2021  
<https://www.nature.com/ng/volumes/53/issues/10>  
[Reviewed earlier]

### **Nature Human Behaviour**

Volume 5 Issue 10, October 2021  
<https://www.nature.com/nathumbehav/volumes/5/issues/10>  
*Editorial* | 19 October 2021

#### **[Description, prediction, explanation](#)**

Description, prediction and explanation are all important in science. We welcome descriptive, predictive and explanatory studies, so long as the work is clear about its aims and uses appropriate methods to achieve its goals.

### **Nature Medicine**

Volume 27 Issue 10, October 2021  
<https://www.nature.com/nm/volumes/27/issues/10>  
[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 22 Issue 10, October 2021  
<https://www.nature.com/nrg/volumes/22/issues/10>  
[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 21 Issue 10, October 2021  
<https://www.nature.com/nri/volumes/21/issues/10>  
[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 20 Issue 10, October 2021  
<https://www.nature.com/nrd/volumes/20/issues/10>  
[Reviewed earlier]

### **New England Journal of Medicine**

October 21, 2021 Vol. 385 No. 17  
<http://www.nejm.org/toc/nejm/medical-journal>  
*Correspondence*

## **SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 31627-1629**

## **Covid-19 Breakthrough Infections in Vaccinated Health Care Workers**

### **Pediatrics**

Vol. 148, Issue 4 1 Oct 2021

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

### **PharmacoEconomics**

Volume 39, issue 10, October 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-10>

[New issue; No digest content identified]

### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 23 Oct 2021)

[No new digest content identified]

### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 23 Oct 2021)

[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 23 Oct 2021)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 23 Oct 2021)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 23 Oct 2021]

*Research Article*

**Bringing the social into vaccination research: Community-led ethnography and trust-building in immunization programs in Sierra Leone**

Luisa Enria, Joseph S. Bangura, Hassan M. Kanu, Joseph A. Kalokoh, Alie D. Timbo, Mohamed Kamara, Maligie Fofanah, Alhassan N. Kamara, Adikalie I. Kamara, Morlai M. Kamara, Ibrahim Sorie Suma, Osman M. Kamara, Alusine M. Kamara, Alhajie O. Kamara, Abu B. Kamara, Emmah Kamara, Shelley Lees, Mark Marchant, Mariama Murray

Research Article | published 22 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258252>

### **Epidemiology of measles cases, vaccine effectiveness, and performance towards measles elimination in The Gambia**

Alieu Sowe, Mbye Njie, Dawda Sowe, Sidat Fofana, Lamin Ceesay, Yaya Camara, Brook Tesfaye, Samba Bah, Alieu K. Bah, Abdoulie K. Baldeh, Bakary D. Dampha, Samba N. Baldeh, Alagie Touray

Research Article | published 21 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258961>

### **Parental acceptance and knowledge of varicella vaccination in relation to socioeconomic in Sweden: A cross-sectional study**

Lisen Arnheim-Dahlström, Natalie Zarabi, Karin Hagen, Goran Bencina

Research Article | published 21 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0256642>

### **Politicization of COVID-19 health-protective behaviors in the United States: Longitudinal and cross-national evidence**

Wolfgang Stroebe, Michelle R. vanDellen, Georgios Abakoumkin, Edward P. Lemay Jr., William M. Schiavone, Maximilian Agostini, Jocelyn J. Bélanger, Ben Gützkow, Jannis Kreienkamp, Anne Margit Reitsema, Jamilah Hanum Abdul Khaiyom, Vjolica Ahmedi, Handan Akkas, Carlos A. Almenara, Mohsin Atta, Sabahat Cigdem Bagci, Sima Basel, Edona Berisha Kida, Allan B. I. Bernardo, Nicholas R. Buttrick, Phatthanakit Chobthamkit, Hoon-Seok Choi, Mioara Cristea, Sára Csaba, Kaja Damnjanović, Ivan Danyliuk, Arobindu Dash, Daniela Di Santo, Karen M. Douglas, Violeta Enea, Daiane Gracieli Faller, Gavan Fitzsimons, Alexandra Gheorghiu, Ángel Gómez, Ali Hamaidia, Qing Han, Mai Helmy, Joevarian Hudiyana, Bertus F. Jeronimus, Ding-Yu Jiang, Veljko Jovanović, Željka Kamenov, Anna Kende, Shian-Ling Keng, Tra Thi Thanh Kieu, Yasin Koc, Kamila Kovyazina, Inna Kozytska, Joshua Krause, Arie W. Kruglanski, Anton Kurapov, Maja Kutlaca, Nóra Anna Lantos, Cokorda Bagus Jaya Lemsmana, Winnifred R. Louis, Adrian Lueders, Najma Iqbal Malik, Anton Martinez, Kira O. McCabe, Jasmina Mehulić, Mirra Noor Milla, Idris Mohammed, Erica Molinario, Manuel Moyano, Hayat Muhammad, Silvana Mula, Hamdi Muluk, Solomiia Myroniuk, Reza Najafi, Claudia F. Nisa, Boglárka Nyúl, Paul A. O'Keefe, Jose Javier Olivas Osuna, Evgeny N. Osin, Joonha Park, Gennaro Pica, Antonio Pierro, Jonas Rees, Elena Resta, Marika Rullo, Michelle K. Ryan, Adil Samekin, Pekka Santtila, Edyta Sasin, Birga M. Schumpe, Heyla A. Selim, Michael Vicente Stanton, Samiah Sultana, Robbie M. Sutton, Eleftheria Tseliou, Akira Utsugi, Jolien Anne van Breen, Caspar J. Van Lissa, Kees Van Veen, Alexandra Vázquez, Robin Wollast, Victoria Wai-Lan Yeung, Somayeh Zand, Iris Lav Žeželj, Bang Zheng, Andreas Zick, Claudia Zúñiga, N. Pontus Leander

Research Article | published 20 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0256740>

### **Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment**

Michele P. Andrasik, Gail B. Broder, Stephaun E. Wallace, Richa Chaturvedi, Nelson L. Michael, Sally Bock, Chris Beyrer, Linda Oseso, Jasmin Aina, Jonathan Lucas, David R. Wilson, James G. Kublin, George A. Mensah

Research Article | published 19 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258858>

### **Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers**

Moza Alishaq, Hanaa Nafady-Hego, Andrew Jeremijenko, Jameela Ali Al Ajmi, Mohamed Elgendy, Suni Vinoy, Sameera Bihi Fareh, Justine Veronica Plaatjies, Mariam Nooh, Nadya Alanzi, Anvar H. Kaleeckal, Ali Nizar Latif, Peter Coyle, Hamed Elgendy, Abdul-Badi Abou-Samra, Adeel Ajwad Butt

Research Article | published 15 Oct 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0258820>

## **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 23 Oct 2021]

[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

October 12, 2021; vol. 118 no. 41

<https://www.pnas.org/content/118/41>

*Research Article*

### **The Strategic Council for Research Excellence, Integrity, and Trust**

Marcia McNutt, France A. Córdova, and David B. Allison

PNAS October 12, 2021 118 (41) e2116647118;

<https://doi.org/10.1073/pnas.2116647118>

We announce the creation of a new body within the National Academies of Sciences, Engineering, and Medicine called the Strategic Council for Research Excellence, Integrity, and Trust, charged with advancing the overall health, quality, and effectiveness of the research enterprise across all domains that fund, execute, disseminate, and apply scientific work in the public interest. By promoting the alignment of incentives and policies, adoption of standard tools, and implementation of proven methods, the Strategic Council seeks to optimize the excellence and trustworthiness of research for the benefit of society...

*Immunology and Inflammation*

*Open Access*

### **Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians**

Luca Hensen, Thi H. O. Nguyen, Louise C. Rowntree, Timon Damelang, Marios Koutsakos, Malet Aban, Aeron Hurt, Kim L. Harland, Maria Auladell, Carolien E. van de Sandt, Anngie Everitt, Cath Blacker, Damian A. Oyong, Jessica R. Loughland, Jessica R. Webb, Bruce D. Wines, P. Mark Hogarth, Katie L. Flanagan, Magdalena Plebanski, Adam Wheatley, Amy W. Chung, Stephen J. Kent, Adrian Miller, E. Bridie Clemens, Peter C. Doherty, Jane Nelson, Jane Davies, Steven Y. C. Tong, and Katherine Kedzierska

PNAS October 12, 2021 118 (41) e2109388118; <https://doi.org/10.1073/pnas.2109388118>

## **Prehospital & Disaster Medicine**

Volume 36 - Issue 5 - October 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 150 September 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/150/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

27 October 2021 Volume 288 Issue 1961

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

## **Public Health**

Volume 199 Pages e1-e4, 1-118 (October 2021)

<https://www.sciencedirect.com/journal/public-health/vol/199/suppl/C>

*Research article Full text access*

**[‘Why are you not dead yet?’ – dimensions and the main driving forces of stigma and discrimination among COVID-19 patients in Sri Lanka](#)**

S. Jayakody, S.A. Hewage, N.D. Wickramasinghe, R.A.P. Piyumanthi, ... C. Arambepola

Pages 10-16

## **Public Health Ethics**

Volume 14, Issue 2, July 2021

<http://phe.oxfordjournals.org/content/current>

*Original Articles*

**[Post-COVID-19 WHO Reform: Ethical Considerations](#)**

Thana C de Campos-Rudinsky

Public Health Ethics, Volume 14, Issue 2, July 2021, Pages 134–147,

<https://doi.org/10.1093/phe/phab011>

*Abstract*

This study argues against the expansive approach to the WHO reform, according to which to be a better global health leader, WHO should do more, be given more power and financial resources, have more operational capacities, and have more teeth by introducing more coercive monitoring and compliance mechanisms to its IHR. The expansive approach is a political problem, whose root cause lies in ethics: WHO’s political overambition is grounded on WHO’s lack of conceptual clarity on what good leadership means and what health (as a human right) means. This study presents this ethical analysis by putting forth an alternative: the humble approach to the WHO reform. It argues that to be a better leader, WHO should do much less and have a much narrower mandate. More specifically, WHO should focus exclusively on coordination efforts, by ensuring truthful, evidence-based, consistent, and timely shared communications regarding PHEIC among WHO member-states and other global

health stakeholders, if the organization desires to be a real global health leader whose authority the international community respects and whose guidance people trust.

### **Public Health Reports**

Volume 136 Issue 5, September/October 2021

<https://journals.sagepub.com/toc/phrg/136/5>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 31 Issue 10, August 2021

<https://journals.sagepub.com/toc/qhra/current>

[Reviewed earlier]

### **Research Ethics**

Volume 17 Issue 4, October 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 23 Oct 2021]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

18 Oct 2021

[\*\*SARS-CoV-2 surveillance in untreated wastewater: detection of viral RNA in a low-resource community in Buenos Aires, Argentina\*\*](#)

Original research | English |

18 Oct 2021

[\*\*COVID-19 vaccine hesitancy and acceptance in Mexico: a web-based nationwide survey\*\*](#)

Original research | English |

18 Oct 2021

[\*\*Implementation of telemedicine in the Americas: Barriers and facilitators\*\*](#)

Opinion and analysis | Spanish |

18 Oct 2021

[\*\*Comparative economic evaluation of renal replacement therapies in Argentina, Costa Rica, and Uruguay\*\*](#)



Original research | Spanish |

### **Risk Analysis**

Volume 41, Issue 9 Pages: 1497-1735 September 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 23 Oct 2021]

*Original Research*

[No new digest content identified]

### **Science**

Volume 374| Issue 6566| 22 Oct 2021

<https://www.science.org/toc/science/current>

*Research Articles*

#### **[Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells](#)**

BY Jose Mateus et al.

22 Oct 2021

*Open Access*

A reduced dose of the Moderna SARS-CoV-2 vaccine induces long-lived T cell and antibody responses comparable to natural infection.

#### **[A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa](#)**

Eduan Wilkinson et al

09 Sep 2021: 423-431

*Open Access*

The early phases of the COVID-19 pandemic in Africa were dominated by European imports, followed by the local generation of variants.

### **Science Translational Medicine**

Volume 13| Issue 616| 20 Oct 2021

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 286 October 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/286/suppl/C>

*Research article Full text access*

#### **[Light at the end of the tunnel: Influence of vaccine availability and vaccination intention on people's consideration of the COVID-19 vaccine](#)**

Haoran Chu, Sixiao Liu  
Article 114315

*Short communication Open access*

**[Value judgments in a COVID-19 vaccination model: A case study in the need for public involvement in health-oriented modelling](#)**

Stephanie Harvard, Eric Winsberg, John Symons, Amin Adibi  
Article 114323

**Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 23 Oct 2021]

[No new digest content identified]

**Theoretical Medicine and Bioethics**

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

**Travel Medicine and Infectious Diseases**

Volume 43 September–October 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/43/suppl/C>

[Reviewed earlier]

**Tropical Medicine & International Health**

Volume 26, Issue 10 Pages: i-iv, 1139-1323 October 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

**Vaccine**

Volume 39, Issue 42 Pages 6183-6340 (8 October 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/42>

*Research article Abstract only*

**[Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010–2020](#)**

Anna N. Chard, Maureen Martinez, Almea Matanock, Ahmed M. Kassem

Pages 6250-6255

*Research article Abstract only*

**[Estimation of oral poliovirus vaccine effectiveness in Afghanistan, 2010–2020](#)**

Anna N. Chard, Maureen Martinez, Almea Matanock, Ahmed M. Kassem

Pages 6250-6255

*Research article Open access*

### **Low COVID-19 vaccine hesitancy in Brazil**

Daniella Campelo Batalha Cox Moore, Marcio Fernandes Nehab, Karla Gonçalves Camacho, Adriana Teixeira Reis, ... Saint Clair dos Santos Gomes Junior  
Pages 6262-6268

*Research article Full text access*

### **Predicting COVID-19 vaccination intention using protection motivation theory and conspiracy beliefs**

Judith Eberhardt, Jonathan Ling  
Pages 6269-6275

*Research article Open access*

### **Microplanning for designing vaccination campaigns in low-resource settings: A geospatial artificial intelligence-based framework**

Thiago Augusto Hernandez Rocha, Dante Grapiuna de Almeida, Arthi Shankar Kozhumam, Núbia Cristina da Silva, ... João Ricardo Nickenig Vissoci  
Pages 6276-6282

*Research article Abstract only*

### **Cost-effectiveness of routine catch-up hepatitis a vaccination in the United States: Dynamic transmission modeling study**

Elamin H. Elbasha, Yoonyoung Choi, Vince Daniels, Michelle G. Goveia  
Pages 6315-6321

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

*Open Access Opinion*

### **Manifesto on the Value of Adult Immunization: "We Know, We Intend, We Advocate"**

by [Raffaele Antonelli-Incalzi](#) et al.

Vaccines 2021, 9(11), 1232; <https://doi.org/10.3390/vaccines9111232> (registering DOI) - 22 Oct 2021  
*Abstract*

Immunization through vaccination is a milestone achievement that has made a tremendous contribution to public health. Historically, immunization programs aimed firstly to protect children, who were disproportionately affected by infectious diseases. However, vaccine-preventable diseases can have significant impacts on adult mortality, health, and quality of life. Despite this, adult vaccinations have historically been overlooked in favor of other health priorities, because their benefits to society were not well recognized. As the general population is aging, the issue of vaccination in older adults is gaining importance. In high-income countries, recommendations for the routine vaccination of older adults have been gradually introduced. The Italian National Immunization Plan is considered to be among the most advanced adult vaccination plans in Europe. However, available data indicate there is low adherence to vaccination recommendations in Italy. The COVID-19 pandemic has exposed the damage that can be caused by an infectious disease, especially among adults and individuals with comorbidities. The aim of this "Manifesto", therefore, is to provide an overview of the existing evidence on the value of adult vaccination, in the Italian context, with a call to action to healthcare providers and health authorities

*Open Access Article*

**Caregivers' Willingness to Vaccinate Their Children against Childhood Diseases and Human Papillomavirus: A Cross-Sectional Study on Vaccine Hesitancy in Malawi**

by [Gbadebo Collins Adeyanju](#) et al.

Vaccines 2021, 9(11), 1231; <https://doi.org/10.3390/vaccines9111231> (registering DOI) - 22 Oct 2021

***Abstract***

Background: Vaccines are among the most effective and cost-efficient public health interventions for promoting child health. However, uptake is considerably affected by vaccine hesitancy. An example is Malawi, with a decline in second vaccine doses and the highest cervical cancer incidence and mortality

***Open Access Article***

**Acceptance of COVID-19 Vaccination in the Elderly: A Cross-Sectional Study in Southern Italy**

by [Francesca Gallè](#) et al.

Vaccines 2021, 9(11), 1222; <https://doi.org/10.3390/vaccines9111222> - 21 Oct 2021

***Abstract***

In Italy, at the end of 2020, a voluntary immunization plan against COVID-19 was introduced, involving elderly among the first target categories. The aim of this study was to assess, through an online questionnaire, the acceptance of COVID-19 vaccination in a sample of [...]

***Open Access Article***

**Attitudes of Parents with Regard to Vaccination of Children against COVID-19 in Poland. A Nationwide Online Survey**

by [Mateusz Babicki](#) et al.

Vaccines 2021, 9(10), 1192; <https://doi.org/10.3390/vaccines9101192> - 17 Oct 2021

***Abstract***

Within a few months, the scientific world achieved a great success, developing effective and safe vaccines against COVID-19. Many countries with full access to vaccines have introduced recommendations for the vaccination of not only people who are at risk of developing severe COVID-19,

**Value in Health**

October 2021 Volume 24 Issue 10 p1391-1542

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....  
.....

**medRxiv**

*medRxiv is a free online archive and distribution server for complete but [unpublished manuscripts](#) (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints - complete but unpublished manuscripts - that describe human health research conducted, analyzed, and interpreted according to scientific principles...*

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 23 Oct 2021]

*Selected Content*

**Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: a descriptive cohort study among 1.1 million vaccinated people in Hong Kong**

Xue Li, Le Gao, Xinning Tong, Vivien K.Y. Chan, Celine S.L. Chui, Francisco Lai, Carlos Wong, Eric Y.F. Wan, Esther W.Y. Chan, Kui Kai Lau, Chak Sing Lau, Ian C.K. Wong  
medRxiv 2021.10.21.21265314; doi: <https://doi.org/10.1101/2021.10.21.21265314>

**COVID-19 Vaccine Perceptions and Uptake in a National Prospective Cohort of Essential Workers**

Karen Lutrick, Holly Groom, Ashley Fowlkes, Kimberly Groover, Manjusha Gaglani, Patrick Rivers, Allison Naleway, Kimberly Nguyen, Meghan Herring, Kayan Dunnigan, Andrew Phillips, Joel Parker, Khaila Prather, Matthew S Thiese, Zoe Baccam, Harmony Tyner, Sarang Yoon  
medRxiv 2021.10.20.21265288; doi: <https://doi.org/10.1101/2021.10.20.21265288>

**Post COVID-19 in children, adolescents, and adults: results of a matched cohort study including more than 150,000 individuals with COVID-19**

Martin Roessler, Falko Tesch, Manuel Batram, Josephine Jacob, Friedrich Loser, Oliver Weidinger, Danny Wende, Annika Vivirito, Nicole Toepfner, Martin Seifert, Oliver Nagel, Christina König, Roland Juckewitz, Jakob Peter Armann, Reinhard Berner, Marina Treskova-Schwarzbach, Dagmar Hertle, Stefan Scholz, Stefan Stern, Pedro Ballesteros, Stefan Baßler, Barbara Bertele, Uwe Repschläger, Nico Richter, Cordula Riederer, Franziska Sobik, Anja Schramm, Claudia Schulte, Lothar Wieler, Jochen Walker, Christa Scheidt-Nave, Jochen Schmitt  
medRxiv 2021.10.21.21265133; doi: <https://doi.org/10.1101/2021.10.21.21265133>

**COVID-19: Knowledge, Perception of Risk, Preparedness and Vaccine Acceptability among Healthcare Workers in Kenya**

Hafso Mohamed Abdulle, Moses Muia Masika, Julius Otieno Oyugi  
medRxiv 2021.10.19.21264712; doi: <https://doi.org/10.1101/2021.10.19.21264712>

**Evidence of transmission from fully vaccinated individuals in a large outbreak of the SARS-CoV-2 Delta variant in Provincetown, Massachusetts**

Katherine J. Siddle, Lydia A. Krasilnikova, Gage K. Moreno, Stephen F. Schaffner, Johanna Vostok, Nicholas A. Fitzgerald, Jacob E. Lemieux, Nikolaos Barkas, Christine Loreth, Ivan Specht, Christopher H. Tomkins-Tinch, Jillian Silbert, Beau Schaeffer, Bradford P. Taylor, Bryn Loftness, Hillary Johnson, Petra L. Schubert, Hanna M. Shephard, Matthew Doucette, Timelia Fink, Andrew S. Lang, Stephanie Baez, John Beauchamp, Scott Hennigan, Erika Buzby, Stephanie Ash, Jessica Brown, Selina Clancy, Seana Cofsky, Luc Gagne, Joshua Hall, Rachel Harrington, Gabrielle L. Gionet, Katherine C. DeRuff, Megan E. Vodzak, Gordon C. Adams, Sabrina T. Dobbins, Sarah D. Slack, Steven K. Reilly, Lisa M. Anderson, Michelle C. Cipicchio, Matthew T. DeFelice, Jonna L. Grimsby, Scott E. Anderson, Brendan S. Blumenstiel, James C. Meldrim, Heather M. Rooke, Gina Vicente, Natasha L. Smith, Katelyn S. Messer, Faye L. Reagan, Zoe M. Mandese, Matthew D. Lee, Marianne C. Ray, Marissa E. Fisher, Maesha A. Ulcena, Corey M. Nolet, Sean E. English, Katie L. Larkin, Kyle Vernest, Sushma Chaluvadi, Deirdre Arvidson, Maurice Melchiono, Theresa Covell, Vaira Harik, Taylor Brock-Fisher, Molly Dunn, Amanda Kearns, William P. Hanage, Clare Bernard, Anthony Philippakis, Niall J Lennon, Stacey B. Gabriel, Glen R. Gallagher, Sandra Smole, Lawrence C. Madoff, Catherine M. Brown, Daniel J. Park, Bronwyn L. MacInnis, Pardis C. Sabeti  
medRxiv 2021.10.20.21265137; doi: <https://doi.org/10.1101/2021.10.20.21265137>

**Lack of Trust, Insufficient knowledge and Risk denial; an in-depth Understanding of Health workers Barriers to uptake of the Covid-19 vaccine at Iganga Hospital Eastern Uganda, and Mengo Hospital Kampala Uganda**

Lubega Muhamadi, Namulema Edith, Waako James, Nazarius Mbona Tumwesigye, Safinah Kisu Museene, Hellen Mukakaarisa, Stefan Swartling Peterson, Anna Mia Ekström  
medRxiv 2021.10.13.21264920; doi: <https://doi.org/10.1101/2021.10.13.21264920>

**Ensemble model estimates of the global burden of measles morbidity and mortality from 2000 to 2019: a modeling study**

Heather Santos, Kirsten Eilertson, Brian Lambert, Sarah Hauryski, Minal Patel, Matthew Ferrari  
medRxiv 2021.08.31.21262916; doi: <https://doi.org/10.1101/2021.08.31.21262916>

**Assessment of knowledge about human papillomavirus vaccination among primary school girls in Arba Minch town, South Ethiopia, 2020. An institution-based cross-sectional study**

Eshetu Yisihak Ukumo, Feleke Gebremeskel, Samuel Abebe, Desta Markos Minanmo, Gebresilasea Gendisha Ukke  
medRxiv 2021.10.16.21264889; doi: <https://doi.org/10.1101/2021.10.16.21264889>

\* \* \* \*

**Think Tanks et al**

**Brookings** [to 23 Oct 2021]

<http://www.brookings.edu/>

*Report*

**Discrimination in the healthcare system is leading to vaccination hesitancy**

Gabriel R. Sanchez, Matt Barreto, Ray Block, Henry Fernandez, and Raymond Foxworth  
Wednesday, October 20, 2021

**Center for Global Development** [to 23 Oct 2021]

<http://www.cgdev.org/page/press-center>

*Accessed 23 Oct 2021*

**Economic and Programmatic Implications for the Covid-19 Vaccine Roll Out in Africa**

Event

10/28/21

Curbing the pandemic while protecting access to [essential health services](#) requires an [ample supply of vaccine](#), a functioning, well-funded delivery system, and careful planning.

**ODA Rules Must Ensure that Vaccine Donations Count for the Poor**

October 21, 2021

After buying up the World's vaccine supply to ensure they can protect their own populations, rich countries have found themselves struggling to use the vaccine surpluses they accumulated. One response has been to donate the spare doses to countries who need them more. This is laudable, and countries who have done so want to receive credit for such actions in their aid statistics—what is known as Official Development Assistance (ODA).

[Euan Ritchie](#), [Anthony McDonnell](#) and [Ranil Dissanayake](#)

### **We Should Track Global Vaccine Manufacturing Better - Here Is Why, and How**

October 21, 2021

Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blog proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world's vaccine manufacturing capacity.

[Anthony McDonnell](#) et al.

**Chatham House** [to 23 Oct 2021]

<https://www.chathamhouse.org/>

*Accessed 23 Oct 2021*

[No new digest content identified]

### **CSIS**

<https://www.csis.org/>

*Accessed 23 Oct 2021*

[No new digest content identified]

### **Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

[No new digest content identified]

**ODI [Overseas Development Institute]** [to 23 Oct 2021]

<https://odi.org/en/publications/>

*Publications*

### **What MDBs (and their shareholders) can do for vaccine equity**

06 October 2021

In late 2020 the World Bank and the Asian Development Bank (AsDB) announced large-scale financing packages to help the rollout of Covid-19 vaccines in low- and middle-income countries. But despite the urgency of doing this to bring the global pandemic to an end, the uptake of these financing packages has so far been slow. Why are committed funds sitting idle at the same time that vaccination programmes are a priority in many countries battling new waves of Covid-19 infections? And at the same time as many activists and world leaders call on G7 leaders to ramp up their contributions to the global vaccination effort?

In this long-read we review some of the factors and bottlenecks that can plausibly explain this low uptake of MDB financing for vaccine purchases from governments in low- and middle-income countries. More importantly, we outline what management and shareholders of MDBs should do to ramp up the use of these financing facilities or deploy resources to support the health response against Covid-19. The fundamental issue has been between the country-based lending model of MDBs and the need to finance and procure a global public good (a low-cost vaccine). MDBs thus need a clearer mandate and dedicated grant financing for global public goods, including vaccine procurement.

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2021. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*